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PREFACE
During my years in graduate school, other than science, the most valuable thing
I have learned is how to grow as a person.
This dissertation about a therapy development originates from the observations
of biological effects in ultrasound imaging. Six years ago, I started working on this
project as an electrical engineer with expertise in signal processing and limited basic
knowledge in biology. However, up to now, I have witnessed the growth of the therapy
development and of myself by absorbing the thoughts of professionals in various fields:
physicists, engineers, biologists and physicians. Advancement occurs when you share
your thoughts and when you encounter individuals who think outside of the box. This
leads you to look at your thoughts at different angles.
I have always been a listener. I don’t necessarily understand everything I’ve heard
about but I try keep them in mind. As time passes, some random experience may
trigger your understanding. I have learned ‘No is not an answer’, anything can be
reasonably possible. You have to accept that you are not always going to be right or
that you know everything. Breaking from such thoughts gives you the willingness to
correct yourself.
Of course, it would be optimal if great things can be achieved at early stages.
But if it doesn’t, it will come as long as you practice patience. Even when you
struggle for a long period, in time, what you have accumulated will start paying
you back. I used to feel guilty having fun instead of working until I went through
deep depression, confused about the meaning of life. It got more and more frustrating
v
when expectations were not achieved, until one day I realized the depression stemmed
from me focusing on trying hard to please others and forgetting to love myself. Once
I understood this, I started to appreciate every little thing happening around me
and gradually learned that one’s life is not about achieving one or several goals but
instead, enjoying and fully utilizing every moment. The inspiration from running,
music or showering may shed light on the solution of an equation, the development
of experiment protocols or explanation of experiment observations.
With patience, you convey your message better, you understand better, you com-
municate better and you learn better.
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1.1 Schematic representation of physics of ultrasound and microbubble
cavitation. (a) An acoustic pressure wave, alternately compresses
(compression phases; dark gray regions) and expands (rarefaction
phases; light areas). (b) Displacement of molecules in a pressure
wave: the black dots represent molecules present in the medium that
are shifted from their equilibrium state when ultrasound is passing
through. (c) and (d) show, respectively, stable and inertial cavitation
of microbubbles. Adapted from (Lentacker et al., 2009) . . . . . . . 5
1.2 Schematic representation of biological effects which may arise during
cavitation and implosion of microbubbles. Microstreams can apply a
shear stress on cell membranes which may result in a transient open-
ing of the cell membranes, so called sonoporation (Sboros , 2008; Wu
et al., 2002; Bao et al., 1997). Shock waves and microjets generated
from bubble collapse create forces that can perforate cell membranes
and even permeabilize blood vessels leading to possible extravasation
and damage to adjacent cells outside blood vessels (Lentacker et al.,
2009; Miller , 2007; Lentacker et al., 2009). . . . . . . . . . . . . . . 7
1.3 Plots of fluorescent cell counts of lethally injured cardiomyocytes
forming microlesions in single frozen sections 1 day post exposure
compared to the ECG premature complexes counted during 1.5 MHz
myocardial contrast echocardiography (MCE) with Definity R© infu-
sion. The dashed line marks the upper limit for diagnostic ultrasound.
Cell count and number of premature heartbeats had a similar depen-
dence on peak rarefactional pressure amplitude (PRPA). Adapted
from (Miller et al., 2014a) . . . . . . . . . . . . . . . . . . . . . . . 8
x
1.4 Examples of heart photographs made one day after ultrasound expo-
sure. Evans blue staining of lethally injured cardiomyocytes and the
corresponding fluorescent image slices with microlesions fluorescence
red for treatment conditions for (a) PRPA = 2 MPa, triggered every
4 heart beats, therapeutic pulse of 5 cycles (b) PRPA = 4 MPa, trig-
gered every 8 heart beats, therapeutic pulse of 10 cycles. Adapted
from (Miller et al., 2014a) . . . . . . . . . . . . . . . . . . . . . . . 9
1.5 Flow chart of the MCET process . . . . . . . . . . . . . . . . . . . 10
2.1 Evans blue staining indicated injured cardiomyocytes for microscope
assessment as shown in (a) within an area noted by MaL (macrole-
sion), where also LV (left ventricle), RV (right ventricle), and SP
(septum) are labeled. An example tissue section of treated heart
muscle is shown in (a) brightfield and (b) fluorescence. The damaged
cardiomyocytes in scattered microlesions appear stained light blue
in the brightfield image, together with erythrocytes and other cells
associated with the colocated microvascular hemorrhage, as shown
in (a). The damaged cardiomyocytes specifically appear fluorescent
red in the relatively high contrast fluorescence image as shown in (b).
The therapeutic ultrasound beam trajectory indicated by the white
arrow in (b) is estimated from the lesion cloud as described in the
text (US: ultrasound). Similarly, (c) brightfield image and (d) fluo-
rescence image of an example tissue section of a sham case are shown.
The background fluorescence includes a few bright spots due to cell
overlap, arterial walls, and other autofluorescent normal structures. 19
2.2 Illustration of a heart tissue slice plane intersecting with layers of the
ventricular wall. (a) Schematic diagram for three elliptic-cylinder
modeled cardiomyocytes oriented differently for each layer: blue for
superficial (S), green for middle (M), and red for deep (D) layer.
(b) Schematic diagram for the orientation of cardiomyocytes in each
layer: blue for superficial (S), green for middle (M), and red for deep
(D) layer. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
2.3 Top view of an elliptic cylinder cell intersected with the cutting plane
at an angle of θ. The cutting edge is GH. . . . . . . . . . . . . . . . 21
2.4 Flowchart for the overall method of macrolesion characterization. . . 23
2.5 Threshold mask as shown in (b) and an edge-detected mask as shown
in (c) were obtained simultaneously from a normalized brightfield
(BF) image as shown in (a). Fusion of these resulted in the tissue
mask as shown in (d). . . . . . . . . . . . . . . . . . . . . . . . . . . 25
xi
2.6 Automatic threshold for fluorescence image has been used to detect
microlesions shown masked on the brightfield image in (b) compared
to original brightfield image in (a). Note: images were zoomed in. . 26
2.7 Three-dimensional stacking of registered image masks allows for vi-
sualization of the employed 3-D model, where the red heart tissue
surface outline is rendered as a result from step 1 (tissue detection),
black marks symbolize downsampled microlesions detected in step 2,
and the therapeutic ultrasound beam (blue line) is characterized from
least square fitting of the microlesion cloud (see text for more details). 27
2.8 Schematic diagram of the procedure for macrolesion characterization.
The stacked 3-D heart model was resliced along the therapeutic beam
in 800-µm-thick steps. At each position along the beam axis noted
by a blue “x, a disk was characterized as illustrated in (a). Each
disk started with a 20 mm diameter and coaxial to the beam and is
graphically identified as the most outer dash circle; the disk diameter
was then progressively reduced as the red arrow implies until a cer-
tain microlesion quantity was reached from a dynamic threshold (see
Fig. 9). The resulting disk then characterizes the local macrolesion
slice and is shown in yellow, surrounded by black solid line. The yel-
low cylinder-like volume as in (b), i.e., stacked disks, is defined as a
macrolesion, characterized by a dynamic thresholding algorithm for
counting enclosed microlesions for each disk step as illustrated in (a)
(US: ultrasound). . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
2.9 For a stained cell number cutoff threshold of 30, the auto adjusted
threshold is plotted as a function of counted stained cells. If only
20 stained cells are counted within the current axial slice, then the
macrolesion radius is set such that approximately 80% of the counted
stained cells are enclosed. . . . . . . . . . . . . . . . . . . . . . . . . 29
2.10 Characterized macrolesion visualization: the same as 2.7, addition-
ally the resulting volumetric macrolesion is shown as yellow disks
along the therapeutic beam. Note that it did not include the distal
cloud of microlesions. The inclusion criteria were chosen to reject vol-
umes with less than 10% microlesion density. In a chronic study, we
plan to explore what microlesion density will cause significant tissue
reduction. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
2.11 Example set of images showing the characterized macrolesion pro-
jected back onto its original 2-D microscopy images with dashed lines
indicating stacked cross-sectioned cylinders and tissue boundary de-
rived from brightfield tissue detection. . . . . . . . . . . . . . . . . . 30
xii
2.12 Characterized features of macrolesions are compared to the measure-
ment of troponin I in plasma samples taken one day after the treat-
ment. The treated group was subdivided into three subgroups being
treated at different time points of the cardiac cycle: R wave (RR, end
diastole), R wave plus 1/3 of the R to R interval (RR/3, end systole),
and R wave plus 2/3 of the R to R interval (2RR/3, mid-diastole). . 32
2.13 In vivo point spread function (PSF) of the therapeutic beam as as-
sessed in terms of lesion density along the axis of the treatment trans-
ducer. Top: lesion density within macrolesion along the therapeutic
beam axis; bottom: lateral cut through macrolesion at axial maxi-
mum (indicated as an x on the top). . . . . . . . . . . . . . . . . . . 33
2.14 Two examples of comparison on visual cell scoring and automatic
scoring derived from the proposed computer-based quantification method
with the cardiomyocyte model. The proposed method gives an area-
based estimation of stained cell number instead of a subjective judg-
ment based on microlesion morphology. . . . . . . . . . . . . . . . . 35
3.1 Schematic illustration (top view and side view) of the experimental
setup. The imaging array and therapeutic transducer were fixed at a
37◦ angle so the acoustic axis of the therapy transducer was parallel
with a specific image line of the sector array. This image line was
identified in a water tank using a line target and marked on the screen
of the ultrasound scanner. This image line was then used to warrant
the acoustic access to the left ventricular wall. Subsequently, the
transducer/probe gantry was translated so the therapy transducer
beam followed the same path as for the previously identified image
line. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
3.2 Employed electric pulse train excitations. Circles in square mod-
ulation (a) and Gaussian modulation (b) pulse trains indicate the
employed negative pressure amplitudes. Note that each spark is a
5-cycle 1.5 MHz tone burst. . . . . . . . . . . . . . . . . . . . . . . 43
3.3 Scatter plot showing comparison of visual score versus auto score.
The auto score was obtained from a computer-aided method (Zhu
et al., 2015a) with piece-wise least square fitting at a break point for
the auto score equal to 15,000. Visual scoring correlates best with
auto scoring for fewer lesion counts, which reveals the difficulty to
assess large number of lesions quantitatively by visual means. . . . 46
xiii
3.4 Therapeutic ultrasound transducer field simulation. (a). FIELD II
simulation of pressure distribution for free field single element ther-
apy transducer. (b). Lesion formation based on the lesion-pressure
dependence; volume narrows the region of lesion formation to where
peak negative pressure is above 2 MPa, i.e. greater than the lesion
formation pressure threshold. The acoustic pressure field represent-
ing the expected lesion region is 2.5 × 32 mm at the level of -6 dB
relative to 4 MPa. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
3.5 Diagram illustrating a macrolesion as characterized from a stack of
histology slices. The heart wall (HW) is depicted in red lines. A cross-
section of the heart is shown as a histological slice (HS), stained with
Evans blue indicating cell necrosis, i.e. microlesions. The ultrasound
beam is indicated as a blue line and arrow (US) and was derived from
least square fitting of microlesions. Along the beam, the shown green
cylindrical disks were characterized from cylindrical volume elements
that contain 95% of the local microlesions. These coaxially stacked
disks form a radially symmetric volume, called the macrolesion (ML),
which is assumed to correlate with the in situ acoustic field. . . . . 49
3.6 Treatment impact for different acoustic pressures. Here included:
(a) macrolesion volume, (b) length of macrolesion and (c) radius of
macrolesion for groups exposed under 2.0 MPa (G), 2.8 MPa (H) and
4.0 MPa (D). Simulations were done for a mean radius of acoustic field
above the lesion formation pressure threshold of 2.0 MPa (PRPA).
Macrolesion volumes appear positively related to acoustic pressure,
where contributions come from the radial direction while the axial
sizes are insignificantly different. . . . . . . . . . . . . . . . . . . . 50
3.7 Treatment impact characterized for re-sliced volume along therapeu-
tic beam. Results for exposures of 2.0, 2.8 and 4.0 MPa PRPA are
shown for: (a) scatter plot of lesion density with least square fit-
ting and zero crossing 0.9 MPa PRPA; (b) scatter plot of microlesion
volume with least square fitting and zero crossing 2.3 MPa PRPA. 51
3.8 Treatment impact for different contrast agent infusion duration. Re-
sults for (a) visual score and (b) microlesion volume for groups in-
fused with contrast agents for 30 s, 100 s, and 300 s, at a rate of 5
µL/kg/min, for groups J, I, and D, respectively. A positively cor-
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for durations of 30 and 100 s are not statistically different. However,
an infusion duration of 300 s significantly differs from the former two
conditions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
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3.9 Treatment impact for different contrast agent infusion rates. Results
are shown for (a) microlesion volume, (b) macrolesion volume and
(c) lesion density for groups infused with contrast agents for 5 min
at a rate of 5 µL/kg/min (D) and 2 min at 12.5 µL/kg/min (E),
i.e. yielding the same total dose. They are not significantly different,
showing that the impact is dominated by the cumulative dose. . . . 53
3.10 Example microscopic brightfield images of treated heart slices. The
histology slice (a) contains sparse microlesions. Note that microle-
sions appear with a light blue stained by Evans blue. The shown his-
tology violates the standard heart model shown in (b). Distributed
myocytes are lying in different tissue layers and with varying orien-
tations. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
3.11 Treatment impact for square and Gaussian pulse modulation schemes.
Results for the impact of individual focal treatment (group B) ver-
sus a swept beam (group D) are shown for (a) the corresponding
macrolesion volume and (b) the observed lesion density. Similar im-
pact is seen between Gaussian modulation and square modulation,
which validates that a swept beam scheme might be a viable method
to shorten treatment duration. . . . . . . . . . . . . . . . . . . . . 56
3.12 Comparison of treatment impact for different injections sites and ul-
trasound aiming strategies. Results show (a) macrolesion volume (b)
and lesion density for two microbubble administration routes, i.e. tail
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3.13 Scatter plot of characterized parameters versus infusion durations.
Results for (a) visual score, (b) microlesion volume, (c) macrolesion
volume and (d) macrolesion mean radius show some linear depen-
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probability to create lesion is accumulative over time. Growth of the
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4.1 Schematic of the positioning setup of the imaging probe and the
therapeutic transducer. For targeting, the rat heart was located at
2.25-cm depth at the edge of the sector, as illustrated on the left.
Subsequently, the therapeutic transducer was moved in so that the
beam followed the same path (dotted gray line) as the previously
identified image line (solid gray line), as illustrated on the right. The
heart was right in the focal zone of the therapeutic transducer (3.8-
cm focal length), as illustrated at the center of the image sector at
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ABSTRACT




Co-Chairs: Oliver D. Kripfgans and Cheri X. Deng
Hypertrophic Cardiomyopathy (HCM), which occurs in 1/500 individuals world-
wide can lead to sudden death in adults without prior symptoms. Echocardiography
is commonly used to diagnose hypertrophic cardiomyopathy. Current treatment in-
volves invasive and high-risk procedures such as surgery or catheter-based ablation of
spetum to potentially prevent left ventricular outflow tract obstruction. A novel tech-
nique, called Myocardial Cavitation-Enabled Therapy (MCET), has been proposed
as a means to achieve minimally invasive myocardial reduction, i.e. heart tissue abla-
tion. MCET aims to target hypertrophic heart muscle over time without substantial
tissue scarring. The treatment employs contrast echocardiography at higher than di-
agnostic pressure amplitudes to produce scattered microlesions (clusters of dead cells)
by cavitating contrast agent microbubbles. The assessment and control of MCET is
explored in three different contexts as follows:
• A computer-aided 3-D quantitative evaluation scheme, for acute studies, is de-
veloped to characterize macrolesions (targeted region for treatment) based on
xxiii
histology sections, including lesion size and lesion density. The characteriza-
tion is based on brightfield and fluorescence histological images as available in
acute preclinical studies. The radially symmetric model employed to charac-
terize macrolesion density is feasible for the study using a single focused beam
to perform treatment. This methodology provides a volume-oriented, quantity-
sensitive therapy evaluation. Results from parametric studies of MCET demon-
strate that the quantitative scoring scheme reduces visual scoring ambiguity,
overcomes the limitation of traditional visual scoring and works for cases with
a large histologically identified lesion count, i.e. has an appropriate dynamic
range for evaluating therapeutic applications. The presented results presented
here have shown that MCET-induced macrolesions grow radially as the acoustic
pressure amplitude increases. Using a swept beam as a new method seems to
be able to shorten treatment time.
• MCET shows great potential as a minimally-invasive myocardial tissue reduc-
tion therapy after long-term healing. Chronic studies of 6-week show the mat-
uration of MCET induced microlesions with quantitative results of the fibrotic
tissue fraction. And the tissue reduction in a HCM rat model is demonstrated
by showing and heart muscle wall shrinkage by about 16%, which is a thera-
peutically useful magnitude. MCET method can be improved by addition of
adjuvant treatment with steroids and hypertension medication to help fibrosis
reduction. Further development and refinement in larger animals of MCET
treatment for HCM should fill the need for a new clinical treatment option.
• Feasibility of detection, quantification and localization for microbubble cavita-
tion is investigated for treatment monitoring and controls. A passive cavitation
imaging algorithm and variations of this algorithm provide spatial information
on the extent of cavitation events. Cavitation sites can be localized with rea-
xxiv
sonable spatial resolution. The described passive imaging algorithm applies to
both systems: Verasonics (an ultrasound research platform) alone transmitting
high intensity focused ultrasound (HIFU) and receiving signals with cavitation
signatures, and Verasonics only for passive receiving with another HIFU sys-
tem for therapeutic exposure. The overall therapy-monitoring scheme is able
to adequately delineate the spatial location of triggered microbubble dynamics





The need for myocardial reduction can arise for Hypertrophic Cardiomyopathy
(HCM) and other ventricular hypertrophies, such as right ventricular hypertrophy
associated with the tetralogy of Fallot, and as such, it represents a substantial public
health concern. HCM is the most common genetic cardiovascular disease, occur-
ring in 1 in 500 people (Maron et al., 2012). Patients may experience shortness of
breath, angina, palpitations, and even sudden death as has occurred in young athletes
(Maron and Maron, 2013). Myocardial hypertrophy leads to the obstruction of the
left ventricular outflow path in up to 75% of patients. About one-third of patients
with obstruction remains symptomatic after pharmacological therapy and are can-
didates for myocardial reduction (Marian, 2009). The gold standard for diagnosis
and treatment follow-up is echocardiography. The standard method for therapeutic
reduction is septal myectomy, specifically, for removing asymmetric septal hypertro-
phy with perturbation of the mitral valve leaflets (Maron et al., 2003b). Nonetheless
alternatives to surgery have been sought using various forms of technology. For ex-
ample, thermal ablation with high intensity focused ultrasound can be used to reduce
cardiac tissue by accumulating focal lesions, but it has limited depth and requires
a large aperture (i.e. open chest in the canine model) (Otsuka et al., 2007). In
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addition, radio-frequency catheter ablation of septal hypertrophy failed to produce
efficacious septal narrowing while leading to a need for pacemaker implantation in
21% of patients (Lawrenz et al., 2011). Transcatheter septal ablation with alcohol,
as an alternative to surgery, has been developed, and it has achieved some success
in terms of safety and efficacy (Leonardi et al., 2010). However, this procedure un-
fortunately has a high incidence of heart blockage requiring permanent pacemakers
in about 20% of cases(Marian, 2009). In addition, there is a substantial risk of seri-
ous arrhythmia arising after healing of the alcohol-induced infarction to scaring with
subsequent cardiac remodeling (Nishimura and Ommen, 2010). The technique of
transcatheter septal ablation has not been widely accepted, and a better less-invasive
alternative to surgery is sorely needed.
Microbubbles cavitate with presence of ultrasound. The potential for cavitation
activity in diagnostic ultrasound was recognized early in safety studies based upon
theoretical analysis (Apfel , 1982; Carstensen and Flynn, 1982). However, at that
time, cavitational bioeffects of pulsed ultrasound were unknown. Without the pres-
ence of exogenous cavitation nuclei, cavitation is not detectable for diagnostic ul-
trasound (Carstensen et al., 2000), and thresholds to induce cavitation activity are
expected to be quite high (Church, 2002). Ultrasound contrast agents were invented
to enhance blood echogenicity with stabilized microbubble suspensions. The highly
non-linear response of the microbubbles provides novel opportunities for diagnostic
imaging (Bruce et al., 2003). The cavitational response to even diagnostic pulses also
leads to a variety of microscale bioeffects in contrast enhanced diagnostic ultrasound,
which are certainly undesirable but of uncertain medical impact (Miller et al., 2008).
Conversely, the ultrasonic cavitational bioeffects have been a boon to a search on new
therapeutic strategies. The activation of microbubbles in the circulatory system for
therapeutic purposes continues to be explored. Ultrasound microbubble activation
therapies have attractive features, including the ability to guide the treatment using
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ultrasound imaging and real-time feedback from the microbubble emissions (Cochran
et al., 2011; Kooiman et al., 2014; Vignon et al., 2013). Prospective treatments
range from transient opening of capillaries, such as the blood-brain barrier (Burgess
and Hynynen, 2014), to complex methods for drug or gene delivery using specially
prepared gaseous delivery vehicles that can be targeted to the desired region for treat-
ment (Ma et al., 2013). These methods have been studied for treatments like gene
therapy, various cancer treatments and thrombolysis (Ibsen et al., 2013; Laing and
McPherson, 2009; Unger et al., 2014).
High pressure amplitude myocardial contrast echocardiography (MCE) has been
shown to lethally injure cardiomyocytes (Miller et al., 2005a). This phenomenon
leads to randomly scattered microlesions involving one or a few cardiomyocytes seen
in histology. The microlesions represent cardiomyocyte loss and, as after a long-
term healing process, they appear to result in fibrous microscar formation with tissue
shrinkage. This presents another attractive opportunity for therapeutic applications.
Based on aforementioned process of tissue shrinkage, Myocardial Cavitation-Enabled
Therapy (MCET) was proposed as a new noninvasive alternative for patients needing
cardiac tissue reduction (Miller et al., 2014a).
Treatment of MCET is guided by the ultrasound used diagnose and characterize
the hypertrophy in need of reduction. The MCET method is non-invasive with mi-
crobubbles doing microsurgery. The scattered nature of the cell loass maintains the
treated region as functional myocardium with microcirculation and electrical con-
ductivity, rather than being cut away by surgery or essentially killed and fixed by
alcohol ablation. It takes advantage of the use of contrast agent microbubbles to pro-
duce scattered sites of ultrasonic cavitation nucleation and microlesion production
in the heart, which may provide a relatively safe means of targeted tissue reduction
therapy. This will represent a significant departure from current practice and a po-
tential breakthrough in care of patients with HCM and other conditions requiring
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myocardial reduction. The dispersed nature of MCET microlesions should prevent
infarction-induced arrhythmia by leaving most of the cardiac tissue unharmed, even in
the target volume. The idea of MCET may become a viable option as a conservative
initial remedy with repeated treatment, or a therapy for patients for whom surgery
is not an option, or even a proactive prophylactic procedure. This development will
significantly improve the prognosis and quality of life for patients living with these
life threatening conditions.
1.2 Therapy Mechanism
Illustrating the therapeutic mechanism of MCET involves several core concepts
that form its technical foundation, requiring careful definitions and a solid back-
ground. Those components are ultrasound, microbubble cavitation, microlesion and
macrolesion. This introductory section will define these terms and explain their rele-
vance.
1.2.1 Physics of Ultrasonic Microbubble Cavitation
Ultrasound is a longitudinal pressure wave with a frequency above 20 kHz. As
schematically shown in Figure 1.1(a), an acoustic pressure wave alternately com-
presses (compression phases; dark gray regions) and expands (rarefaction phases;
light areas) the medium through which it travels. Hence, when an ultrasound wave
is passing through a medium, the molecules inside the medium can be actually dis-
placed as illustrated in Figure 1.1(b). The black dots represent molecules present in
the medium that are shifted from their equilibrium state. They are compressed at
high pressure and expanded at low pressure (Leighton, 2007).
The original intention of gas microbubble deployment in ultrasound imaging was
to provide contrast an enhancement, as microbubbles improve the scattering of the ul-
trasound wave, and are, therefore, also called “echo contrast agents” (Calliada et al.,
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Figure 1.1: Schematic representation of physics of ultrasound and microbubble cavita-
tion. (a) An acoustic pressure wave, alternately compresses (compression
phases; dark gray regions) and expands (rarefaction phases; light areas).
(b) Displacement of molecules in a pressure wave: the black dots represent
molecules present in the medium that are shifted from their equilibrium
state when ultrasound is passing through. (c) and (d) show, respectively,
stable and inertial cavitation of microbubbles. Adapted from (Lentacker
et al., 2009) .
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1998). In this context, “microbubbles” and “contrast agents” are used interchange-
ably throughout this dissertation.
Microbubbles can be as simple as air-filled bubbles of micrometer sizes, but mi-
crobubbles in this work are composed of a perfluorocarbon gas core surrounded by
a stabilizing shell, as are all currently commercially available ultrasound contrast
agents, e.g., Definity R©(Lantheus Medical Imaging, Inc., N. Billerica, MA) (Ignee
et al., 2016). This structure prevents gas diffusion out of the microbubble which
drastically enhances their stability and circulation time in blood.
Ultrasonic microbubble cavitation is defined as the process of microbubbles
interacting with an ultrasound field (Fowlkes and Holland , 2000). As illustrated in
Figure 1.1(c) and (d), microbubbles that are exposed to ultrasound start to cavitate.
Specifically, cavitating microbubbles alternate between shrinking and expanding as a
result of, respectively, the compressive (high) and rarefactive (low) pressure phases
of the ultrasound wave.
Cavitation is classified into stable cavitation (SC) and inertial cavitation (IC)
(McLaughlan et al., 2010). Stable cavitation (so named non-inertial cavitation) com-
prises stable, low amplitude oscillation of the microbubbles with resonance frequencies
depending on bubble size and other properties (Figure 1.1(c)). Such stable oscilla-
tions create strong liquid flows around the microbubbles, the so-called microstreams.
Microstreams can apply shear stress on cell membranes which may result in a tran-
sient opening of the cell membranes (Sboros , 2008; Wu et al., 2002) (Figure 1.2).
In response to peak rarefactional pressure amplitude (PRPA)s in excess of the in-
ertial cavitation threshold, the microbubbles grow rapidly during the rarefaction
phase, until they collapse due to the inertia of the inrushing fluid. This cavitation
results in the fragmentation of the microbubbles into many smaller microbubbles
(Figure 1.1(d)). This type of cavitation is called inertial cavitation (Newman et al.,
2001; Newman and Bettinger , 2007). During the collapse of the microbubbles, shock
6
waves are generated in the fluid near the microbubble (Figure 1.2). Finally, jet for-
mation can also occur when a collapsing microbubble is located close to a surface like
a cell membrane. In this case, an asymmetrical collapse takes place, which results
in the formation of a liquid jet towards the surface. The shock waves and microjets
create forces that can perforate cell membranes and even permeabilize blood vessels
(Lentacker et al., 2009).
Figure 1.2: Schematic representation of biological effects which may arise during cav-
itation and implosion of microbubbles. Microstreams can apply a shear
stress on cell membranes which may result in a transient opening of the
cell membranes, so called sonoporation (Sboros , 2008; Wu et al., 2002;
Bao et al., 1997). Shock waves and microjets generated from bubble
collapse create forces that can perforate cell membranes and even per-
meabilize blood vessels leading to possible extravasation and damage to
adjacent cells outside blood vessels (Lentacker et al., 2009; Miller , 2007;
Lentacker et al., 2009).
1.2.2 Microlesion and Macrolesion
Studies have demonstrated that an in vivo PRPA threshold (Figure 1.3) exists for
MCE to generate premature electrocardiographic complexes and lethal injury of car-
diomyocytes in an animal model (Miller et al., 2005a). This phenomenon leads to ran-
domly scattered microlesions involving one or a few lethally injured cardiomyocytes
as seen in histology within a confined region of millimeters named macrolesion. The
injured cardiomyocytes represented by the microlesions appear to gradually resolve
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with minimal fibrous scar formation as followed through a 6-week healing process
(Miller et al., 2005b). This cardiomyocyte loss forms the basis of tissue shrinkage
induction.
Figure 1.3: Plots of fluorescent cell counts of lethally injured cardiomyocytes forming
microlesions in single frozen sections 1 day post exposure compared to the
ECG premature complexes counted during 1.5 MHz MCE with Definity R©
infusion. The dashed line marks the upper limit for diagnostic ultrasound.
Cell count and number of premature heartbeats had a similar dependence
on PRPA. Adapted from (Miller et al., 2014a)
After MCET treatment, a macrolesion is created in which the myocardial volume
experiences a ultrasound field pressure above the PRPA threshold (Zhu et al., 2015a).
As illustrated in Figure 1.4, macrolesions identified by dark color resulting from Evans
blue leakage in heart phaotographs are of different dimensions depending on their
exposure conditions. At higher magnification imaging for fluorescent histological
slices, a bulk of scattered microlesions of different densities within macroleions can be
identified. The distribution of microlesions is associated with that of ultrasonically
cavitated microbubbles in the myocardium.
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Figure 1.4: Examples of heart photographs made one day after ultrasound exposure.
Evans blue staining of lethally injured cardiomyocytes and the corre-
sponding fluorescent image slices with microlesions fluorescence red for
treatment conditions for (a) PRPA = 2 MPa, triggered every 4 heart
beats, therapeutic pulse of 5 cycles (b) PRPA = 4 MPa, triggered every 8
heart beats, therapeutic pulse of 10 cycles. Adapted from (Miller et al.,
2014a)
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1.3 Process of MCET Therapy
MCET presents a minimally invasive treatment for myocardial reduction. As illus-
trated in Figure 1.5 ultrasound contrast agent microbubbles are continuously infused
intravenously during treatment. With the presence of contrast agents in the myocar-
dial capillaries identified by MCE hyperechogenicity, intermittent contrast destruction
are facilitated using transcutanuous focused ultrasound therapy transducers. Ultra-
sonic exposures are triggered every N cardiac cycles to allow microbubble reperfusion
after destruction, so that microbubble cavitation induced scattered histologically de-
finable microlesions gradually accumulate to the desired density level (Miller et al.,
2014a). The scattered microlesions are created within a targeted volumetric macrole-
sion by focusing ultrasound energy. The microlesions represent cardiomyocyte loss
and lead to tissue shrinkage after the healing process. The fractional macrolesion
is the site where tissue shrinkage is intended, with the tissue reduction portion pro-
portional to microlesion distribution density, i.e. total damaged cardiomyocytes over
affected volume, assuming the tissue loss equal to the volume of eventually removed
microlesions.
Figure 1.5: Flow chart of the MCET process
1.4 Dissertation Overview
The following chapters of this dissertation will delve more deeply into the devel-
opment of MCET. In particular, the first two chapters will concentrate on acute
studies in a rat model. The first chapter will discuss a three-dimensional analysis
revealing microlesions created within the treated macrolesion. The second chapter
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will focus on the tuning of key parameters involved in MCET and discussion in a
quantitative manner, for pre-clinical treatment plans for myocardial lesion creation
and properties. The third chapter will inspect the long-term effects of MCET over
6 weeks in rat models. The fourth chapter will investigate treatment monitoring in
terms of cavitation. Finally, the dissertation summary and directions for possible
future work will be addressed. Each chapter will contain an introductory section to
provide necessary background material so that the chapter can be read independently
from the rest of the dissertation. A more detailed outline of the dissertation is given
below.
Chapter II provides a three-dimensional analysis of stacked heart tissue histology
sections revealing microlesions. It presents an effective means to characterize the
overall impact or the “macrolesion” created in the volume of interest. The quantita-
tive image analysis overcomes the problem of optimization of the treatment caused by
the uncertainties in the visual scoring of microlesion accumulation after therapy-level
treatment. This work was published in the journal “IEEE Transactions on Biomedical
Engineering” (Zhu et al., 2015a).
Chapter III compliments Chapter II by investigating the tuning of key parameters
involved in MCET and paving the way for pre-clinical treatment planning of myocar-
dial lesion creation thereof, in a quantitative manner. The resulting assessment of
the therapeutic effect drives parameter adjustment to optimize MCET ultrasound
parameters and administration of microbubble strategies to achieve efficacious effect
. This work was published in the journal “Journal of Therapeutic Ultrasound” (Zhu
et al., 2015b).
Chapter IV discusses the healing process and adjuvant treatments over time after
MCET, leading to eventual myocardial reduction, i.e. decrease in heart wall thickness.
Chapter V describes a MCET platform with therapeutic capability and treat-
ment monitoring. It investigates possible schemes based on microbubble cavitation
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feedbacks.
Chapter VI concludes the dissertation with a summary and a discussion on the
outlook for future extensions and refinement of the current research portfolio.
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CHAPTER II
Characterization of Macrolesions Induced by
MCET
2.1 Introduction
Hypertrophic cardiomyopathy (HCM), involving enlargement and hyperplasia of
the myocardium, occurs in at least one out of 500 people. Sudden death is the most
visible and unpredictable consequence of Hypertrophic Cardiomyopathy (HCM), oc-
curring without warning signs or symptoms. It has been reported that HCM is the
most common cause of sudden death in young people, and is the most frequent cause
of sudden death in US competitive athletes (Maron and Maron, 2013). Although
pharmacologic therapies have exhibited significant positive effects, there remain sub-
stantial undesired side effects, leaving approximately a third of patients as candidates
for myocardial reduction (Marian, 2009).
The definitive treatment for HCM is surgical myectomy (Ommen and Nishimura,
2004), which involves resection of a small portion of the interventricular septum at its
base. Less-invasive alternatives have been explored using a variety of techniques, most
commonly an endovascular procedure. However, the need for permanent pacing, the
inability to address concomitant anatomic abnormalities and the uncertainty about
the long-term effects of having caused substantial myocardial necrosis and scaring
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are undesirable. Other approaches such as thermal ablation (Otsuka et al., 2007) or
histotripsy (Xu et al., 2004) reduce cardiac tissue by accumulating ultrasonic focal
lesions.
For decades, ultrasonic bioeffects from microbubble inertial cavitation have been
discussed for their therapeutic potentials (Miller et al., 2008). Concurrent stud-
ies have investigated cavitation-induced microvessel and cell injuries (Chen et al.,
2012). A novel technique using contrast echocardiography using higher than diagnos-
tic pressure amplitudes, named Myocardial Contrast Enabled Therapy (MCET), is
hypothesized to induce a fractional macrolesion with sparse and histologically defin-
able microlesions, which in turn shrink the diseased heart muscle without substantial
scaring (Miller et al., 2005b).
Currently, therapeutic ultrasound has great potential in medicine as a noninva-
sive method to treat tumors, promote hemostasis, and treat other diseases due to its
ability to penetrate deeply and deposit thermal or mechanical energy at a specific
site with submillimeter accuracy. Various imaging modalities, including x-ray, com-
puted tomography, magnetic resonance imaging, and ultrasound imaging, can provide
precise targeting and therapy monitoring (Vaezy et al., 2001).
Passive cavitation imaging has been demonstrated for potential use with continuous-
wave high-intensity focused ultrasound thermal ablation (Gyöngy and Coussios , 2010)
and for pulsed-wave ultrasound therapy insonations (Haworth et al., 2012). A system
for microbubble-mediated sonothrombolysis utilizing therapy guidance and cavitation
imaging has been developed (Vignon et al., 2013).
Myocardial Cavitation-Enabled Therapy (MCET) is performed under the guid-
ance of echocardiography. Ventricular premature complexes and blood pressure can
provide temporal feedback (Miller et al., 2014a), while inertial cavitation mapping
combined with anatomical imaging could delineate the spatial accumulation of car-
diomyocytic response.
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To evaluate the effectiveness of MCET treatment and modulate its treatment
parameters, such as ultrasound amplitude, contrast dose, and treatment duration,
an evaluation scheme is needed for characterizing microlesions. In previous stud-
ies, myocardial necrosis (Miller et al., 2005b), (Miller et al., 2005a) was evaluated
qualitatively by visual identification and scoring of Evans blue-stained cells in frozen
histological slices of heart tissue (Miller et al., 2011). However, visual scoring only
yields a limited 1-D descriptor, i.e., scalar information of damaged cells assessed for
each tissue slice, which is far from adequate to describe a comprehensive treatment
outcome for tuning therapeutic inputs. For example, a qualitative score of 58,790
more than 23,560 helped make relative judgments about the optimum exposure pa-
rameters in terms of overall induced impact, but it gave no information about the
amount of tissue reduction. Thus, an objective and quantitative scoring is needed to
precisely determine treatment outcome and volume-based treatment. Spatial distri-
bution evaluation is essential to ultimately develop a safe and effective therapeutic
application.
Numerous methods have been devised for cellular and histological analysis. Molec-
ular imaging, defined as the visual representation, characterization, and quantification
of biological processes at cellular and subcellular levels, could be used to noninvasively
detect and monitor cancer treatments (Weissleder , 2002). It enables tumor localiza-
tion, spatial visualization of specific molecular markers, and biological processes that
influence tumor behavior and/or response to therapy (Weissleder , 2006).
Regarding cellular microscopy, computational imaging provides multidimensional
and quantitative image analysis, enabling mathematical modeling of cell biology. Em-
ployed process steps include image acquisition and preprocessing, registration, seg-
mentation, volume rendering, etc. (Eils and Athale, 2003). Image segmentation,
including thresholding, region growing, and cluster- ing, plays an important role in
characterizing contents of medical images (Pham et al., 2000).
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This chapter describes a scheme for MCET characterization in acute preclinical
studies (Zhu et al., 2015a). A computer-aided histological evaluation of MCET-
induced macrolesions has been implemented to quantify treatment outcome. The
point of the presented method is to provide the volumetric macrolesion determina-
tion to approximate the expected amount of tissue reduction, which was not available
from the qualitative visual score. Two-dimensional brightfield and fluorescence im-
ages were evaluated by an algorithm, which automatically identified microlesions, and
characterized the volume-oriented fractional macrolesion. Subsequently, this method
can be applied to optimize ultrasound pulse parameters, exposure duration, and con-
trast agent dose for MCET treatment of HCM, which would require up to 25% vol-vol
tissue reduction in some myocardial areas.
2.2 Methods and Materials
2.2.1 Animal and Tissue Preparation
In concomitant research designed to optimize the timing of pulses for MCET,
tissue samples were collected and prepared for histological evaluation. For this study,
these samples were utilized for development of computer-aided evaluation. Briefly,
in vivo animal procedures were conducted on 20 male Sprague-Dawley rats (Charles
River, Wilmington, MA, USA) and five sham rats weighing 331 ± 33 g under the
approval and guidance of the University Committee on Use and Care of Animals. All
rats in the treated group were injected with Definity R© (Lantheus Medical Imaging,
Inc., N. Billerica, MA) at a rate of 5 L/kg/min. MCET was performed with 2 ms
period 4 kHz pulse repetition frequency (PRF) 1.5 MHz ultrasound burst of five cycle
pulses at 4.0 MPa peak rarefactional pressure amplitude (PRPA) by use of a 1.9 cm
diameter and 3.8 cm focus single element therapy transducer, triggered at one beat
out of four heart beats. The therapeutic transducer was focused approximately 0.5
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cm into the myocardium (Miller et al., 2014a). While the distance to the myocardium
might change a few millimeters, the effect of choice of cardiac phase was studied in
Miller et al. (Miller et al., 2014b) and found to not be significant. Before being
exposed to 5 minutes of therapy, all rats were injected with Evans blue, which has
been proven to be a dependable stain for histological determination of cell necrosis
(Jacyn Baker and Mock , 1994). After being frozen in compound (Tissue-Tek, Sakura
Finetek USA, Inc., Torrance, CA, USA) on dry ice, each heart was dissected to provide
samples covering the entire exposed myocardial volume. Up to 40 sections, 10 µm
thick, for each heart were cut every 200 µm into the sample to cover about 5 mm
of the dissected portion of the heart. Two hundred micron spacing was set to avoid
possible overlap of stained cardiomyocytes in adjacent sections and thoroughly sample
the cardiac volume. However, it should be noted that some stained cells present in
between sections were not actually observed, but assumed by extrapolation to have
the same fractional lesion area over the 190 µm unsampled space.
2.2.2 Cardiomyocyte Scoring
Besides the proposed automatic characterization scheme, visual scoring and mea-
surement of troponin I in plasma were performed to evaluate cardiomyocyte injuries.
Visual scoring was based on Evans blue staining as described previously (Miller et al.,
2014a). Troponin I was analyzed from plasma samples analyzed one day after eu-
thanasia with an ELISA assay kit (Rat Cardiac Tn-I (ultra sensitivity), Life Diag-
nostics, Inc., West Chester, PA, USA). This cardiac enzyme is a sensitive indicator
of cardiac injury in rodents (O’brien et al., 2006).
2.2.3 Microscope Image Acquisition
To enable computer-aided evaluation, both brightfield and fluorescence images
were obtained for each tissue-section through a microscope camera system (SPOT
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Flex, Diagnostic Instruments, Inc., Sterling Heights, MI, USA) via fluorescent stere-
omicroscopy (LeicaMZFLIII, Leica Microscopy Systems, Ltd., Heerbrugg, Switzer-
land) with a high resolution and large field of view objective (Leica Plan APO 1.6x,
Leica Microsystems, Ltd., Heerbrugg, Switzerland). The images were acquired as 16
bit 4,096 by 4,096 pixel, RGB, covering the entire tissue sections. One image set of
treated myocardium at the approximate midpoint of the treated zone is shown in
Figure 2.1(a) and (b); a sham image set is shown in Figure 2.1(c) and (d). Macrole-
sion is a volume defined as a bulk of the microlesions within the target area, where
a microlesion was defined simply as a local collection of one or a few damaged car-
diomyocytes. An example showing 3D macrolesion projection onto 2D is identified
by MaL (macrolesion) shown in Figure 2.1(a). Left ventricle (LV), right ventricle
(RV), and septum (SP) are also labeled. The damaged cardiomyocytes in scattered
microlesions appear stained light blue in the brightfield image, together with ery-
throcytes and other cells associated with the colocated microvascular hemorrhage, as
shown in Figure 2.1(a). The damaged cardiomyocytes specifically appear fluorescent
red in the relatively high contrast fluorescence image as shown in Figure 2.1(b). In
contrast, normal heart tissue appears grayer in the brightfield image and darker in the
fluorescence image. The therapeutic ultrasound beam path projected onto the 2-D
image is estimated from the lesion cloud as shown in Figure 2.1(b). Brightfield images
were taken using auto exposure to provide morphologic information and fluorescence
images were taken using a constant exposure to provide constant and quantitative
lesion contrast information.
2.2.4 Cardiomyocyte Modeling
An average cross-sectional area (AC) for one cardiomyocyte sliced in a tissue sec-
tion was estimated based on a mathematical model, which then gave an approximation
of the number of stained cells by dividing the total injured area by the estimated AC
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Figure 2.1: Evans blue staining indicated injured cardiomyocytes for microscope as-
sessment as shown in (a) within an area noted by MaL (macrolesion),
where also LV (left ventricle), RV (right ventricle), and SP (septum)
are labeled. An example tissue section of treated heart muscle is shown
in (a) brightfield and (b) fluorescence. The damaged cardiomyocytes in
scattered microlesions appear stained light blue in the brightfield image,
together with erythrocytes and other cells associated with the colocated
microvascular hemorrhage, as shown in (a). The damaged cardiomyocytes
specifically appear fluorescent red in the relatively high contrast fluores-
cence image as shown in (b). The therapeutic ultrasound beam trajectory
indicated by the white arrow in (b) is estimated from the lesion cloud as
described in the text (US: ultrasound). Similarly, (c) brightfield image
and (d) fluorescence image of an example tissue section of a sham case are
shown. The background fluorescence includes a few bright spots due to
cell overlap, arterial walls, and other autofluorescent normal structures.
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Table 2.1: Single cardiomyocyte geometry model
Parameter Abbreviation Value Unit
Cell length l 113.4±0.8 µm
Cell width w 28.9±0.4 µm
Cell depth d 17.6±0.4 µm
. A cardiac myocyte cell was geometrically modeled as an elliptic cylinder with cell
dimensions summarized in Table 2.1 based on previous work (Bassien-Capsa et al.,
2006). The left ventricular wall comprises three strands of different longitudinal align-
ment: superficial (subepicardial) noted as S, middle noted as M, and deep (subendo-
cardial) noted as D. The myocyte model approximated the superficial “layer” at an
angle of 15◦ with respect to the long axis of the left ventricular inlet, occupying 25%
of the wall thickness, the middle “layer” circumferentially arranged occupying 56% of
the wall thickness, and the deep “layer” radiating longitudinally accounting for 19%
of the wall thickness (Ho, 2009).
Figure 2.2: Illustration of a heart tissue slice plane intersecting with layers of the
ventricular wall. (a) Schematic diagram for three elliptic-cylinder modeled
cardiomyocytes oriented differently for each layer: blue for superficial (S),
green for middle (M), and red for deep (D) layer. (b) Schematic diagram
for the orientation of cardiomyocytes in each layer: blue for superficial
(S), green for middle (M), and red for deep (D) layer.
As illustrated in Figure 2.2, a slice plane intersects with layers of different cell
orientation, resulting in variable cross-sectional areas. The average cross-sectional
cell area AC is then given by Equation 2.1
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AC = ĀSPS + ĀMPM + ĀDPD (2.1)
where ĀS, ĀM , and ĀD are average areas for the three layers: S, M, and D. PS,
PM , and PD are the fractional volume percentages of each layer for the overall wall
thickness, namely PS = 25%, PM =56%, and PD =19%. For the superficial layer, we
assumed that the cutoff plane did not reach the edge so that the cross section was
always strictly an ellipse. Thus, cross-sectional areas for superficial and deep layers
(Equation 2.2 and 2.3) were both considered as ellipses.












Figure 2.3: Top view of an elliptic cylinder cell intersected with the cutting plane at
an angle of θ. The cutting edge is GH.
For the middle layer, the intersection plane was always a rectangle with length
equal to l, and width GH as depicted in Figure 2.3 and determined by the orientation








with −w 6 x 6 w, −d 6 y 6 d, intersects with the cutting line Equation 2.5
y = tan θ · x+ h (2.5)
with 0 6 x 6 π/2, 0 6 y 6 hmax(θ) at points G(x1, y1) and H(x2, y2), if and only
if x,y have real solutions. For a certain cutting angle θ, the maximum value that
h could achieve is when the cutting line is tangent to the ellipse. Thus, hmax is a
function of θ. Thus, the length of the cutting edge GH, LGH , is a function of θ and
h as Equation 2.6
LGH(h, θ) =
√
(x1(h, θ)− x2(h, θ))2 + (y1(h, θ)− y2(h, θ))2 (2.6)
We assume that θ and h are uniformly distributed variables within their range,















, 0 6 h 6 hmax(θ)
0, otherwise
(2.8)
where p indicates the probability density function for p(θ) and p(h). The average
cross-sectional area barAM in this case is Equation 2.9











LGH(h, θ)P (h, θ)dhdθ (2.10)
Finally, given the previous relationships, an average cross-sectional area, barAC ,
of 2,399 µm2 can be computed. The pixel size for all 2-D digital images is 15.7 µm2.
Thus, one cell occupies approximately 2,399 µm2/(15.7µm2/pixel), that is 153 pixel
in the acquired images. An approximation for the number of stained cardiomyocytes
could then be inferred.
2.2.5 Lesion Characterization
To reduce computation complexity and save computation memory, the red chan-
nel, of all the data was first extracted. All the images were preprocessed to remove
uneven illumination and zero padded ready for registration before feeding into the
lesion characterization processing. Background illumination for both brightfield im-
ages and fluorescence images was estimated using a Gaussian low-pass filter (Qu et al.,
2012), that was then subtracted from the original images. The normalized images
were processed following the steps shown in Figure 2.4. The main steps to charac-
terize macrolesions include: 1) tissue detection; 2) microlesion detection; 3) image
registration and 3-D stacking; 4) therapeutic beam estimation; and 5) macrolesion
characterization.
Figure 2.4: Flowchart for the overall method of macrolesion characterization.
Tissue detection and microlesion detection were first done based on 2-D images
to form microlesion masks, which contain the morphologic information of the heart
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as well as stained cell regions. Image registration was then performed on microlesion
masks to reconstruct a volume-based model according to the morphology of the heart.
The therapeutic beam was estimated from the 3-D stacked microlesions, and finally
a macrolesion was characterized along the therapeutic beam.
Step 1: Tissue detection. The main objective in this step is to segment the
tissue portion based on morphologic information from brightfield images to constrain
the subsequent characterization. Brightfield images [see Figure 2.1(a) and (c)] were
downsampled first to be segmented and then upsampled back after segmentation to
decrease computational load. A threshold mask as shown in Figure 2.5(b) and an
edge-detected mask as shown in Figure 2.5(c) were obtained simultaneously from a
normalized brightfield image as the example shown in Figure 2.5(a), which was then
fused together giving the tissue mask as shown in Figure 2.5(d).
Step 2: Microlesion detection. Starting with an initial guess of 10% for the lesion
density, two lesion masks were obtained from thresholding brightfield and fluorescence
images. An automatic threshold, described later, for the fluorescence image was then
determined from the statistics of pixel values within the mutual mask of the two lesion
masks. An example of a lesion mask on top of a zoomed original brightfield image
Figure 2.6(a) is shown in Figure 2.6(b) illustrating the morphologies of the detected
lesions.
Step 3: Image registration and 3-D stacking. To achieve volume-based character-
ization, 2-D lesion masks were stacked to 3-D according to the information provided
through neighboring brightfield images from the tissue slide stack, i.e., by means of the
transformation information from rigid image registration. Stacking registered mask
images allows for visualization of the employed 3-D model as shown in Figure 2.7,
where the red contour is rendering the tissue edges as resulting from step 1, and black
marks symbolize microlesions detected in step 2. The inner red oval shape is the ex-
clusion representing the in- ner surface of the LV. For the purpose to visualize the
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Figure 2.5: Threshold mask as shown in (b) and an edge-detected mask as shown
in (c) were obtained simultaneously from a normalized brightfield (BF)
image as shown in (a). Fusion of these resulted in the tissue mask as
shown in (d).
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Figure 2.6: Automatic threshold for fluorescence image has been used to detect mi-
crolesions shown masked on the brightfield image in (b) compared to
original brightfield image in (a). Note: images were zoomed in.
overall effect of treatment, high-resolution image showing the detailed morphology of
individual cell is unnecessary; thus, 32 times downsampled microlesions symbolized
by black marks are displayed representing the trend of lesion density. However, the
full resolution is used for characterization.
Step 4: Therapeutic beam estimation. The therapeutic beam vector shown as a
blue line with an arrow in Figure 2.7 was characterized by least square line fitting
from the detected microlesions, excluding autofluorescing blood vessels and other
nonmicrolesion microstructures, which were considered as noise.
Step 5: Macrolesion characterization. The stacked 3-D heart model was resliced
along the therapeutic beam in 800-µm-thick steps. Note that the reslices here are not
tissue-sections but slices perpendicular to the identified ultrasound beam. At each
position along the beam axis, a disk was characterized as illustrated in Figure 2.8(a):
each such slice was first populated with a 20-mm-diameter disk coaxial to the beam;
each disk was then progressively reduced in size until a certain microlesion quantity
was reached from a dynamic threshold, the criterion of which is explained below.
Disks were characterized individually and then stacked together resulting in a final
macrolesion as shown in Figure 2.8(b).
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Figure 2.7: Three-dimensional stacking of registered image masks allows for visualiza-
tion of the employed 3-D model, where the red heart tissue surface outline
is rendered as a result from step 1 (tissue detection), black marks sym-
bolize downsampled microlesions detected in step 2, and the therapeutic
ultrasound beam (blue line) is characterized from least square fitting of
the microlesion cloud (see text for more details).
To determine the dynamic radius mentioned earlier, a dynamic percentage value
of overall stained cells within a maximum slice volume is computed. The threshold
is a piecewise function of total number of stained cells and is shown in Figure 2.10.
Here
p(h) =
 if N > N0, T = T0;if N < N0, T = max(T0(1− e−N), T0), (2.11)
where N indicates the total number of stained cells detected, N0 is a cutoff thresh-
old for piecewise function, and T indicates the percentage threshold for radius select-
ing with a constant T0 as a maximum. As illustrated in Figure 2.9, the example here
sets N0 = 30, T0 = 95%.
The in vivo point spread function (PSF) of the therapeutic beam was characterized
as a function of space by first sampling along the therapeutic beam interrogating
coaxial cylinders of λ (1 mm) diameter and quarter λ length. Then, at the point of
maximum axial lesion density, the lateral direction was sampled with coaxial rings of
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Figure 2.8: Schematic diagram of the procedure for macrolesion characterization. The
stacked 3-D heart model was resliced along the therapeutic beam in 800-
µm-thick steps. At each position along the beam axis noted by a blue “x,
a disk was characterized as illustrated in (a). Each disk started with a 20
mm diameter and coaxial to the beam and is graphically identified as the
most outer dash circle; the disk diameter was then progressively reduced
as the red arrow implies until a certain microlesion quantity was reached
from a dynamic threshold (see Fig. 9). The resulting disk then charac-
terizes the local macrolesion slice and is shown in yellow, surrounded by
black solid line. The yellow cylinder-like volume as in (b), i.e., stacked
disks, is defined as a macrolesion, characterized by a dynamic thresh-
olding algorithm for counting enclosed microlesions for each disk step as
illustrated in (a) (US: ultrasound).
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one-eighth λ width and quarter λ height.
Figure 2.9: For a stained cell number cutoff threshold of 30, the auto adjusted thresh-
old is plotted as a function of counted stained cells. If only 20 stained
cells are counted within the current axial slice, then the macrolesion ra-




A radially symmetric macrolesion was characterized via stepping disks of various
radius determined by the local distribution of microlesions. An example is shown in
Figure 2.10. An example of a 3-D macrolesion intersecting with one of the original
2-D microscopy images is shown in Figure 2.11 with a delineated boundary indicat-
ing macrolesion projection and tissue boundary characterized from brightfield tissue
detection.
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Figure 2.10: Characterized macrolesion visualization: the same as 2.7, additionally
the resulting volumetric macrolesion is shown as yellow disks along the
therapeutic beam. Note that it did not include the distal cloud of mi-
crolesions. The inclusion criteria were chosen to reject volumes with less
than 10% microlesion density. In a chronic study, we plan to explore
what microlesion density will cause significant tissue reduction.
Figure 2.11: Example set of images showing the characterized macrolesion projected
back onto its original 2-D microscopy images with dashed lines indicat-




As described in a concomitant study (Miller et al., 2014a), the treated group
of rats was subdivided into three groups, with five rats in each group. They were
treated at three different time points of the cardiac cycle: at the onset of R wave
(RR, end diastole), at the R wave plus one-third of the R to R interval (RR/3, end
systole) and at the R wave plus two thirds of RR (2RR/3, mid- diastole). Results for
macrolesions characterized for all 20 rats are presented in Figure 2.12 using boxplots.
For each box, the central mark is the median, the edges of the box are the 25th and
75th percentiles, the whiskers extend to the most extreme data points not considered
outliers, and outliers are plotted individually. The normal range was defined as greater
than q3 + 1.5(q3 − q1) or smaller than q1 − 1.5(q3 − q1), where q1 and q3 are the 25th
and 75th percentiles, respectively. Corresponding median values for treated groups
are reported in Table 2.2. The results show no significant variation between treated
groups, which agree with the visual scoring results from the concomitant study. The
summarized results for the treated group of 15 rats compared to sham group show
significant macrolesions with a median volume of 87.3 µL of 14.0% lesion density,
2.7 mm macrolesion radius, and 4.8 mm macrolesion length compared to zero lesion
density, radius, and length for the sham group. This overall result was consistent
with the measurements of troponin, which were also indicative of total cardiomyocyte
necrosis.
2.3.3 Point Spread Function
The in vivo PSF of the therapeutic beam in terms of lesion density was character-
ized for one rat affected by an extreme long therapeutic path through the myocardium,
as shown in Figure 2.13.
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Figure 2.12: Characterized features of macrolesions are compared to the measure-
ment of troponin I in plasma samples taken one day after the treatment.
The treated group was subdivided into three subgroups being treated at
different time points of the cardiac cycle: R wave (RR, end diastole), R
wave plus 1/3 of the R to R interval (RR/3, end systole), and R wave
plus 2/3 of the R to R interval (2RR/3, mid-diastole).
Table 2.2: Summary of results. Median values summarized for Figure 2.12 for sham
group, treated group, (RR, RR/3, 2RR/3) of five rats in each at different
exposure time with respect to a cardiac cycle and all treated rats of 15.
Sham(5) RR(5) RR/3(5) 2RR/3(5) Treated(15)
Macrolesion volume [µL] 0 81.1 84.8 120.7 87.3
Cardiac troponin I [ng/mL] 0 1.1 0.9 0.7 0.9
Lesion density in macrole-
sion volume [%]
0 10.8 13.7 16.2 14.0
Mean radius in macrolesion
volume [mm]
0 2.5 2.7 2.7 2.7
Length of macrolesion vol-
ume [mm]
0 4.8 4.8 4.8 4.8
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Figure 2.13: In vivo PSF of the therapeutic beam as assessed in terms of lesion den-
sity along the axis of the treatment transducer. Top: lesion density
within macrolesion along the therapeutic beam axis; bottom: lateral cut
through macrolesion at axial maximum (indicated as an x on the top).
2.4 Discussion
This computer-aided histological evaluation appears to provide robust character-
ization of the macrolesion formed by the accumulation of microlesions based on the
following considerations.
2.4.1 Therapeutic Beam Estimation
Occurrence of cavitation events induces the here observed damage to cardiac my-
ocytes. It is expected that the lesion density would be uniform within the beam
profile, where the acoustic pressure exceeds the cavitation threshold, assuming that
the contrast agent in the myocardium is uniformly distributed. However, lesion uni-
formity could be disrupted by variable superthreshold acoustic pressures, which may
injure more than one cell per cavitation event. Hence, we expect the lesion density
trend of the microlesion to be dictated by the acoustic beam profile as well as pro-
cesses involving motion of the myocardium. For example, breathing motion leads
to smearing out the accumulation effect of the treatment, which then is not shaped
strictly according to therapeutic beam. Thus, in turn, the therapeutic beam estima-
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tion is affected. A decreasing trend of the lesion density was observed along the axial
direction, possibly due to acoustic attenuation caused by contrast agents in the LV.
The lateral PSF profile was obtained at the maximum of the axial response, which
was regarded as the volume of interest of the therapy. The in vivo PSF -6 dB lateral
width of approximately 2.8 mm agrees reasonably with the 3.5 mm beam diameter
of the therapy transducer as obtained from a free-field water tank calibration. The
in vivo lateral beam width may be affected by aberration dis- tortion of the sound
wave propagating through overlying tissue layers, thus narrowing the beam diameter
with pressure amplitudes above the threshold required for cavitation. Additionally,
acoustic attenuation will reduce the in situ pressure amplitude and also narrow the
beam cross section containing pressure amplitudes required for microlesion creation.
2.4.2 Cardiomyocyte Model Validation
A total of 160 manually selected cells according to the morphology appearing in
brightfield images were taken an average to obtain estimation of area for a cell of 2,719
µm2 versus 2,398 µm2 from the theoretical geometric model. The 12% deviation of
the estimation model from the selected estimation comes from bias on selecting large
identifiable cells on the manual side and the variation from the cell orientation from
the modeling side.
2.4.3 Cardiomyocyte Cell Scoring Validation
The Evans blue staining found in frozen sections, one day after therapy, identi-
fies lethally injured cells resulting from microlesions (Miller et al., 2005b), (Vaezy
et al., 2001). Therefore, the total determination of the macrolesion as a fraction of
the tissue volume provides a first approximation to the amount of tissue reduction
expected from the treatment. The desired reduction would be about 20%, which
could be expanded beyond the single focus treatment described here by moving the
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beam to provide the needed therapeutic reduction in larger (i.e., human) hearts. The
simple visual scoring of the stained cells provides only a qualitative measure of the
microlesion effect, particularly for high densities of microlesions seen in the treat-
ments intended for therapeutic tissue reduction, which only approximate the more
accurate image analysis values (see Figure 2.14). In addition, the qualitative visual
scores fail to give a total fractional reduction throughout the treated volume, which
is provided by the reconstruction of the volume and the macrolesion determination.
The cell identification scheme counts pixels rather than cells assuming an overall con-
stant statistical mean multiplier for pixel to cell size conversion, by which the pixel
counting and subse- quent area to number of cells conversion is independent of the
at times complicated cell morphology. The automatic scheme of stained cell identi-
fication seems reasonable compared to visual scoring as shown in Figure 2.14. The
cases of large accumulations of stained cells were often difficult to score visually re-
sulting in qualitative results rather than actual cell count. In contrast, the proposed
computer-based characterization method is objective and quantitative and overcomes
the limitation of large number of cells.
Figure 2.14: Two examples of comparison on visual cell scoring and automatic scoring
derived from the proposed computer-based quantification method with
the cardiomyocyte model. The proposed method gives an area-based
estimation of stained cell number instead of a subjective judgment based
on microlesion morphology.
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2.4.4 Lesion Characterization Criterion
The volume estimation of macrolesions considered local le- sion density as well
as total lesion number. Additionally, a dynamic radius cutoff criterion was used
that depends on the number of the stained cells. Using a constant threshold for
stained cell intensity would not affect the shape of a well-generated dense lesion due
to the large number of microlesions in the macrolesion volume, but would affect a
sparse macrolesion due to its low number density of microlesions. Thus, a dynamic
threshold was introduced.
2.5 Conclusion
A computer-aided 3-D objective evaluation scheme has been developed to char-
acterize macrolesions, including lesion size and lesion density, for MCET to reduce
myocardial tissue, based on brightfield and fluorescence images as available in acute
preclinical studies. The radially symmetric model employed to characterize macrole-
sion density is feasible for the study using a single focused beam. This methodology
reduces visual scoring ambiguity and provides a volume oriented, quantity- sensitive
therapy evaluation. The significance of characterized macrolesion compared to sham
group demonstrates that the evaluation scheme is robust against noise. Future imple-
mentations of MCET involve formulating a set of optimized treatment parameters to
create a desired total volume reduction based on lesion density within the target vol-
ume. In particular, we are interested in the microlesion density and macrolesion size,
as both determine the anticipated myocardium reduction. The proposed evaluation
scheme could possibly assist quantifying other therapeutic applications resulting in
sparse effects, such as drug delivery, gene therapy, and blood brain barrier opening.
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CHAPTER III
Quantitative Assessment of Damage During
MCET: A Parametric Study in a Rodent Model
3.1 Introduction
Hypertrophic Cardiomyopathy (HCM) is a common genetic cardiovascular dis-
ease, which is usually clinically recognized by a maximal left ventricular wall thickness
greater than 15 mm (Gersh et al., 2011). This globally prevalent disease, reported
in about 0.2% (i.e., 1:500) of the general population, is the most frequent cause of
sudden death in young people and can lead to functional disability from heart failure
and stroke Maron and Maron (2013). The traditional treatment for Hypertrophic
Cardiomyopathy (HCM) to reduce myocardium is septal myectomy. This surgical
method removes septal hypertrophy, which possibly leads to perturbation of mitral
valve leaflets Marian (2009). An innovative therapeutic scheme, named Myocardial
Cavitation Enabled Therapy (MCET), has been proposed as a means to achieve min-
imally invasive myocardial reduction by cavitating contrast agent microbubbles with
ultrasound to produce a fractional macrolesion containing sparse and histologically
definable microlesions Miller et al. (2014a). There are several ways of controlling
cavitation here. Cavitation is enabled by the injection of ultrasound contrast agents.
These will enable cavitation only in the focal region of the transducer and thus only
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there lead to microlesion formation in the myocardium. Second, ultrasound cavi-
tation is dependent on sound pressure amplitude. In vivo experiments reveal that
cavitation-induced lesions take place at peak rarefactional pressures larger than 2
MPa as obtained under free field conditions. In this case ECG is monitored for pre-
mature complexes. It has been seen that the occurrence of premature complexes is
directly correlated with cavitation events Miller et al. (2011).
As a potential tissue reduction therapy, Myocardial Cavitation-Enabled Ther-
apy (MCET) avoids open-chest surgery and is hypothesized to allow healing with
minimal scar formation, resulting in shrinkage of the cardiac treatment volume. This
ultrasound microbubble-enabled method additionally provides the possibility of guid-
ing and monitoring via quantifying feedback from the microbubble emissions.
To optimize MCET ultrasound parameters and administration of microbubble
settings, assessment of the therapeutic effect is needed to assist parameter adjustment.
Efforts in computerized analysis have been made to aid diagnostics and therapy for
being fast, objective and quantitative. Methods have been developed for computed
tomographic angiography for the purposes of detecting heart diseases (Zhou et al.,
2012)(Bouraoui et al., 2010) and for quantification of coronary arterial stenosis (Xu
et al., 2012). Automatic detection of pulmonary embolism has also been used in CT
angiography (Zhou et al., 2003) (Bouma et al., 2009). Quantitative ultrasound has
been employed in diagnosis of osteoporosis (Moayyeri et al., 2012), as well as in at-risk
pregnancies with three-dimensional sonographic measurement of blood volume flow
in umbilical cords (Pinter et al., 2012). Three-dimensional high-frequency ultrasound
data also has been processed to offer a quantitative evaluation of cancerous lymph
nodes at the microscopic level (Mamou et al., 2010).
For MCET, a quantitative method for assessing the distribution and total ac-
cumulation of myocardial necrosis based on Evans blue-stained cells in the tissue
histology slices was developed previously (Zhu et al., 2015a) and is used in this study.
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This chapter investigates the tuning of various parameters involved in MCET and
paves the way for pre-clinical treatment planning of myocardial lesion creation and
properties thereof, in a quantitative manner.
One important and practical aspect of MCET is managing the buildup of mi-
crolesions and macrolesions to achieve a desired amount of myocardium reduction
in larger pre-clinical models as well as, ultimately, in the clinic. Acoustic pressure
amplitude, contrast dose and treatment duration are adjustable variables. The para-
metric exploration of various conditions will assist in the search for feasible treatment
conditions that allow for fast lesion creation with a 15-20% microlesion density and
a large axial and lateral dimension. Another desirable factor for practical clinical
implementation is the treatment efficiency. Instead of treating a single focal spot as
done in our previous study (Miller et al., 2014a), a scanned beam would allow for a
more rapid accumulation of lesions in a larger target treatment volume.
Our method of computer-aided histology analysis was developed using relatively
high exposure parameters to reflect therapeutic treatment conditions (Pinter et al.,
2012). This provided a means to reconstruct the tissue volume containing microlesions
and their distribution, which can then be integrated to yield the potential fraction
of tissue reduction. For validation, a visual scoring method was used in tandem, in
which lethally injured cells indicated by fluorescent staining in frozen sections were
counted. The visual method has been the gold standard for quantifying cell death
by counting the absolute number of stained cells. However, when the number of
stained cells becomes large, as for treatment (rather than exploring bioeffects), the
visual method becomes a qualitative scoring method, which was suspected to yield
inaccurate results for the validation for the computer-aided method. The purpose of
this study was to analyze several exposure groups, which had reduced, sub-therapeutic
treatment effects, using quantitative visual scoring for comparison to the computer-
aided analysis.
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3.2 Methods and Materials
3.2.1 Experimental Conditions
To make MCET amenable to clinical translation, the evaluation of B-mode echogenic-
ity (more generally backscatter), physiological responses, i.e. premature complexes
and visual scoring (Miller et al., 2015) is employed. For this study tissue samples
were collected and prepared for histological evaluation. Specifically, these samples
underwent quantitative analyses aimed to assist the treatment planning. In vivo
animal procedures were conducted on fifty male Sprague-Dawley rats (Charles River,
Wilmington, MA, USA) including five sham rats weighing 352± 30 g. Approval and
guidance of all animal work was done by the University Committee on Use and Care of
Animals. All rats in the treated group were injected with Definity R©(Lantheus Medi-
cal Imaging, Inc., N. Billerica, MA) at a rate of 5 or 12.5 µL/kg/min. Microbubbles
suspended and diluted in sterile saline were infused via a tail vein or jugular vein
catheter (gauge # 24) starting 15 seconds before ultrasound exposure and concluding
with the end of exposure. MCET was performed with ultrasound bursts of five cycle
pulses at a center frequency of 1.5 MHz and a pulse repetition frequency of 4 kHz.
The ultrasound exposure system consisted of a function generator for generating a
pulse train (model 3314A function generator, Hewlett Packard Co., Palo Alto CA),
an arbitrary waveform generator for amplitude modulation of the pulse train (model
33220A, Agilent Technologies, Loveland CO), a power amplifier (A-500, Electronic
Navigation Industries, Rochester NY) and a 1.5 MHz single element therapy trans-
ducer (Panametrics A3464, Olympus, Waltham, MA). The therapy transducer was a
standard single-element focused transducer, with a 1.9 cm diameter and 3.8 cm focal
length. The treatment was targeted with the aid of diagnostic ultrasound imaging
(GE Vivid 7 with S-10 phased array, GE Healthcare, Jupiter FL, USA) operated
at 10 MHz with a 5 cm focal depth, as previously described (Miller et al., 2015).
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The setup scheme as illustrated in Figure 3.1 provided targeting of the therapy beam
and for low-power imaging of the heart during exposure. The imaging array and
therapeutic transducer were fixed at a 37◦ angle such that the acoustic axis of the
therapy transducer is parallel with one image line of the sector array. This image line
was identified in a water tank using a line target and marked on the screen of the
ultrasound scanner. Then this image line was used to evaluate acoustic access to the
left ventricular wall. Subsequently the transducer/probe gantry was translated such
that the therapy transducer beam aimed along the same fixed path as the image line
identified in the image to pass through the window between the ribs (vertical axis)
and between the sternum and the left lung. Burst emissions were triggered from the
ECG signal at every four heartbeats end-systole. Prior to ultrasound exposure, all
rats were injected with Evans blue, a reliable histological stain for lethal injury of
cardiomyocytes (Miller et al., 2015).
Figure 3.1: Schematic illustration (top view and side view) of the experimental setup.
The imaging array and therapeutic transducer were fixed at a 37◦ angle
so the acoustic axis of the therapy transducer was parallel with a specific
image line of the sector array. This image line was identified in a wa-
ter tank using a line target and marked on the screen of the ultrasound
scanner. This image line was then used to warrant the acoustic access to
the left ventricular wall. Subsequently, the transducer/probe gantry was
translated so the therapy transducer beam followed the same path as for
the previously identified image line.
The study was conducted with groups of five rats each and given letter designa-
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Table 3.1: Table of sets of conditions used for respective groups of rats, with a cohort
of 5 animals each. Group F acted as a sham and calibration group, as







Modulation Infusion Rate Treatment
Duration
A Tail 4 MPa Square 5 µL/kg/min 5 min
B Jugular 4 MPa Square 5 µL/kg/min 5 min
C Jugular 4 MPa Square 5 µL/kg/min 5 min
D Jugular 4 MPa Gaussian 5 µL/kg/min 5 min
E Jugular 4 MPa Gaussian 12.5 µL/kg/min 2 min
G Tail 2 MPa Gaussian 5 µL/kg/min 5 min
H Tail 2.8 MPa Gaussian 5 µL/kg/min 5 min
I Tail 4 MPa Gaussian 5 µL/kg/min 100 s
J Tail 4 MPa Gaussian 5 µL/kg/min 30 s
tions to identify the specific set of conditions in each group. Groups A to J were
designed specifically to test treatment effects for different parameters, as listed in Ta-
ble 3.1. Except for Group G and H, all rats were exposed to ultrasound with a peak
rarefactional pressure amplitude (PRPA) of 4 MPa. The pulses in the center of the
focal region were measured in a water bath using a calibrated hydrophone with a 0.2
mm diameter aperture (model HMA-0200, Onda Corp., Sunnyvale, CA) to acquire
the point spread function and the electro-acoustic transfer function. Comparison of
groups A and B tested the influence of catheter placement, with the jugular vein
giving a central and larger vein access than the tail vein. Groups B and C were
compared to test the effect of aiming ultrasound near ribs. Those two comparisons
were performed intentionally to test experimental perturbations.
Groups B and D compared the results of treatment using square versus Gaussian
pulse train modulations of the acoustic pressure. The single element transducer de-
livered a Gaussian envelope pulse train, such that the full-width half maximum of the
Gaussian modulation was 2 ms. This modulation scheme was to simulate an exposure
that would be experienced by contrast agent in the presence of a sweeping ultrasound
beam, as found in a diagnostic imaging setup (Miller et al., 2007). To reduce treat-
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ment times for larger treatment volumes such a beam could be implemented as a
sweeping therapy beam and is thus included in the tested exposure conditions. Note
that only the pulse train envelope is Gaussian modulated. Each individual pulse is a
constant amplitude five-cycle tone burst (see Figure 3.2). The amplitude modulation
was set to give zero exposure unless a modulation-envelope signal was triggered. The
envelope signal was either a 2 ms square pulse with a constant amplitude of 4 MPa
PRPA or a Gaussian modulation function that produced a 2 ms pulse with ampli-
tudes greater than 2 MPa PRPA. The Gaussian modulation was designed to emulate
a scanned ultrasound beam from a clinical ultrasound scanner, with approximately
56 frames per second (fps).
Figure 3.2: Employed electric pulse train excitations. Circles in square modulation
(a) and Gaussian modulation (b) pulse trains indicate the employed neg-
ative pressure amplitudes. Note that each spark is a 5-cycle 1.5 MHz tone
burst.
Different contrast agent dose rates were tested by comparing Groups D and E. The
previous rate was 5 µL/kg/min, representing the recommended dose for diagnostic
applications (Miller et al., 2014a). A higher infusion rate of 12.5 µL/kg/min was
tested for the possibility of using a higher dose in therapeutic applications, which
may reduce treatment durations.
Comparison between Groups G, H and D evaluated the dependence of lesion
formation on acoustic pressure. The three groups were respectively exposed to ul-
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trasound fields of 2, 2.8 and 4 MPa PRPA. Groups J, I and D, on the other hand,
evaluated microlesion accumulation by varying the treatment duration, i.e. adjusting
the contrast infusion duration. Groups G, H, I and J were specifically treated with
sub-therapeutic parameters with reduced treatment impact on cell survival. Correla-
tion between acoustic pressure, treatment duration and induced microlesion density
was intended to establish some dynamic range for microlesion induction.
Finally, Group F was a sham and calibration control group, in which each rat
received the full 4 MPa therapy exposure before the contrast agent infusion started.
Results in groups are presented in boxplots. For each box, the central mark is
the median, the edges of the box are the 25th and 75th percentiles, the whiskers
extend to the most extreme data points not considered outliers, and outliers are
plotted individually. The normal range was defined as q3 + 1.5(q3 − q1) or smaller
than q1− 1.5(q3− q1), where q1 and q3 are the 25th and 75th percentiles, respectively.
3.2.2 Cardiomyocyte Scoring
Rat hearts were harvested and scored one day after exposure as described in
previous work (Miller et al., 2015). Briefly, up to forty 10 µm thick frozen sections
were made from the treated volume in each heart. A quantitative method for assessing
the distribution and total accumulation of myocardial necrosis is based on Evans blue-
staining and was developed previously (Zhu et al., 2015a). Microlesions were identified
by fluorescence microscopy and photographs of each section. Image registration was
then performed to digitally stack the frozen sections in 3D and to reconstruct a model
of the heart morphology in the entire sampled region showing the three-dimensional
distribution of microlesions. The microlesion fraction of the tissue within the focal
zone was calculated to estimate the potential fractional volume of tissue reduction
that was achieved. Quantitative results were characterized in terms of microlesion
volume, macrolesion volume, microlesion lesion density and dimensions of the radially
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symmetric approximated macrolesion.
In addition to the computer-aided assessment, traditional visual scoring was used
to evaluate myocardial necrosis qualitatively by visual identification and quantita-
tively by scoring of Evans blue-stained cells using fluorescence microscopy (Miller
et al., 2015). Automatic scores were obtained from dividing the geometric microlesion
volume by a constant conversion factor acquired from a geometry based cardiomy-
ocyte model (Zhu et al., 2015a).
3.2.3 Therapeutic Field Simulation
The acoustic field, assuming a water path, for the employed single element thera-
peutic transducer was simulated in FIELD II (Jensen and Svendsen, 1992), a widely
used ultrasound simulation program. A 1.9 cm diameter concave single element trans-
ducer with 3.8 cm focus excited at 1.5 MHz with a 5-cycle burst was modeled. The
time period between two successive bursts being 250 µs apart (4 kHz pulse repetition
frequency (PRF)) were significantly larger than the 3 µs indivisual pulse length. Thus
they were considered to have no interference on each others acoustic field. Figure 3.3
(a) shows a normalized field reflecting the maximum exposed pressure during one
burst. The effective region of sound pressures with amplitudes above the acoustic
pressure threshold of 2 MPa is indicated in Figure 3.3 (b). By revolving this shown
region along the lateral (x=0 mm) axis, the effective volume, denoted as an axisym-
metric rotational model, was calculated. This simulation intended to associate in situ
acoustic field with the formed lesion.
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Figure 3.3: Scatter plot showing comparison of visual score versus auto score. The
auto score was obtained from a computer-aided method (Zhu et al., 2015a)
with piece-wise least square fitting at a break point for the auto score
equal to 15,000. Visual scoring correlates best with auto scoring for fewer
lesion counts, which reveals the difficulty to assess large number of lesions
quantitatively by visual means.
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3.3 Results
3.3.1 Quantitative Computer-Guided Lesion Analysis
The previous study (Miller et al., 2014a) was limited by a low dynamic range with
respect to the number of induced lesions. Current results span a large range of number
of lesions per area on histology, which therefore allows for a more critical evaluation of
the performance comparison between visual and automatic scoring. Data presented
in this study reach to tens of thousands of lesions, a range that is difficult to assess
quantitatively by traditional visual scoring. Figure 3.4 shows visual scores plotted
versus auto scores (obtained from computer-aided algorithm) for all groups listed in
Table 3.1. The data can be segmented in two regions: low counts ranging from 0 to
15,000 and high counts from 15,000 to 80,000 (both with respect to the auto score),
respectively. A linear least square fit of the form y = a1 ·x, was performed for the low
lesion count segment and is shown in red and extended as blue in Figure 3.4. Another
linear least square fit, now of the form y = a2 ·x+b, was performed for the high lesion
count segment and is shown in red in Figure 3.4. Best-fit coefficients were found as:
a1 = 1.52, a2 = 0.19; and b=15,216, with a1 greater than 1 would mean that visual
scoring counted more cells, a2 being so low shows that visual scoring counted groups
of cells as one. This result clearly showed the ”saturation” effect of the visual scoring
method for high cell counts.
3.3.2 Acoustic Pressure Dependence
3.3.2.1 Macrolesion volumes
Macrolesion dimensions are in part dictated by the therapy beam geometry as
illustrated in Figure 3.5. Lesion lengths (axial) and lesion diameters (lateral and
elevational) are determined by the point spread function of the therapy transducer
and the acoustic pressure of the transmitted wave. In other words, the volumetric
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Figure 3.4: Therapeutic ultrasound transducer field simulation. (a). FIELD II simu-
lation of pressure distribution for free field single element therapy trans-
ducer. (b). Lesion formation based on the lesion-pressure dependence;
volume narrows the region of lesion formation to where peak negative
pressure is above 2 MPa, i.e. greater than the lesion formation pressure
threshold. The acoustic pressure field representing the expected lesion
region is 2.5 × 32 mm at the level of -6 dB relative to 4 MPa.
region of the acoustic wave that bears pressure amplitudes above the pressure pL
required for lesion formation, will contribute to the therapy. This volumetric region
grows as the pressure amplitude at the focus grows and thus larger acoustic pressures
yield larger lesion count. Macrolesion dimensions are also dictated by the spatial
availability of cells and contrast agent. The simulation gave an acoustic field of
2.5 × 32 mm at the level of -6 dB relative to 4 MPa as shown in Figure 3.3 (b),
representing the expected lesion region. In vivo results for the parametric acoustic
pressure amplitude cases 2.0 (G), 2.8 (H), and 4.0 MPa (D) are illustrated in Figure 3.6
using boxplots. Frequently, the axial dimension was limited by the thickness of the
myocardium with the therapy beam penetrating the left ventricle entirely before the
pressure amplitude fell below the threshold pL. Likewise, the therapy beam pressure
rose above pL before entering the myocardium. Therefore an increase in pressure at
the focus will only show limited increase in the axial lesion size. Radial macrolesion
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expansion is hyperlinear and follows the prediction of the simulation shown as the
plotted curve in Figure 3.6 (c). Simulations were done to compute the average radius
of the acoustic beam above the hypothesized threshold pL (2.0 MPa).
Figure 3.5: Diagram illustrating a macrolesion as characterized from a stack of histol-
ogy slices. The heart wall (HW) is depicted in red lines. A cross-section of
the heart is shown as a histological slice (HS), stained with Evans blue in-
dicating cell necrosis, i.e. microlesions. The ultrasound beam is indicated
as a blue line and arrow (US) and was derived from least square fitting
of microlesions. Along the beam, the shown green cylindrical disks were
characterized from cylindrical volume elements that contain 95% of the
local microlesions. These coaxially stacked disks form a radially symmet-
ric volume, called the macrolesion (ML), which is assumed to correlate
with the in situ acoustic field.
3.3.2.2 Microlesion Characteristics
The spatial variation in lesion density was analyzed with respect to the therapeutic
beam geometry. Specifically, lesion density was plotted as a function of local pressure
amplitudes. Reslicing of the therapeutic beam volume was facilitated by placing
axially oriented disks. Stacking them along the therapeutic beam as illustrated in
Figure 3.5 in green, allowed for plotting of lesion density as a function of local in situ
pressure amplitudes. Least square fitting shown as a blue line in Figure 3.7 (a) resulted
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Figure 3.6: Treatment impact for different acoustic pressures. Here included: (a)
macrolesion volume, (b) length of macrolesion and (c) radius of macrole-
sion for groups exposed under 2.0 MPa (G), 2.8 MPa (H) and 4.0 MPa
(D). Simulations were done for a mean radius of acoustic field above the
lesion formation pressure threshold of 2.0 MPa (PRPA). Macrolesion vol-
umes appear positively related to acoustic pressure, where contributions
come from the radial direction while the axial sizes are insignificantly
different.
in y = 4.52x−4.07, with 0% lesion density occurring at 0.9 MPa indicated by the red
circle. The microlesion volumes for resliced disks versus different acoustic amplitudes
are plotted in Figure 3.7 (b) with least square fitting resulting in y = 57.2x − 130.0
and zero microlesion volume occurring at 2.3 MPa indicated by the red circle.
3.3.3 Contrast Agent Availability Versus Macrolesion Characteristics
As alluded to in the previous section, macrolesion dimensions are dictated by
several experimental conditions, including contrast agent availability. More available
agent will likely generate more lesions. On the other hand, more contrast agent per
unit time may lead to agent induced acoustic shadowing and a diminished in situ
pressure wave amplitude. Results for changes in contrast agent availability are shown
next.
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Figure 3.7: Treatment impact characterized for re-sliced volume along therapeutic
beam. Results for exposures of 2.0, 2.8 and 4.0 MPa PRPA are shown
for: (a) scatter plot of lesion density with least square fitting and zero
crossing 0.9 MPa PRPA; (b) scatter plot of microlesion volume with least
square fitting and zero crossing 2.3 MPa PRPA.
3.3.3.1 Infusion duration
At first a constant infusion rate of 5 µL/kg/min was tested for three infusion
durations, namely 30, 100 and 300 seconds, for groups J, I and D, respectively. Under
ultrasound exposure, increase in contrast infusion time allows for higher deposition
of total number of microbubbles. Figure 3.8 shows a positively correlated number of
generated lesions for the respective total infusion duration. Differences in visual score
and microlesion volume for durations of 30 and 100 s are not statistically different.
However, a 300 s infusion duration shows a significant increase relative to the former
two conditions with respect to the characterized microlesion volume. Specifically,
the microlesion volume increases from 10, to 30, to 300 s is not linear and will be
addressed in the Discussion section.
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Figure 3.8: Treatment impact for different contrast agent infusion duration. Results
for (a) visual score and (b) microlesion volume for groups infused with
contrast agents for 30 s, 100 s, and 300 s, at a rate of 5 µL/kg/min,
for groups J, I, and D, respectively. A positively correlated number of
generated lesions is seen for the respective total infusion duration. Dif-
ferences in visual score and microlesion volume for durations of 30 and
100 s are not statistically different. However, an infusion duration of 300
s significantly differs from the former two conditions.
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3.3.3.2 Infusion rate
Here a constant total dose of contrast agent (25 µL/kg) was tested for two infusion
rates, namely 5 µL/kg/min for 5 mins and 12.5 L/kg/min for 2 mins, for groups D
and E respectively. A higher infusion rate, i.e. more agent per unit time, may
lead to agent-induced acoustic shadowing and a diminished in situ wave pressure
amplitude. Figure 3.9 shows no significantly different number of generated lesions for
the respective infusion rates. Note that microlesion volume here refers to the total
volume of all induced microlesions over the entire myocardium, which is not identical
to the shown microlesion volume within the characterized macrolesion (macrolesion
volume times lesion density).
Figure 3.9: Treatment impact for different contrast agent infusion rates. Results are
shown for (a) microlesion volume, (b) macrolesion volume and (c) lesion
density for groups infused with contrast agents for 5 min at a rate of 5
µL/kg/min (D) and 2 min at 12.5 µL/kg/min (E), i.e. yielding the same
total dose. They are not significantly different, showing that the impact
is dominated by the cumulative dose.
3.3.4 Therapy Beam Sweeping
In this experiment, Gaussian modulation was employed to mimic therapy beam
sweeping. It was observed as shown in Figure 3.10 that both the resulting macrolesion
volume as well as the microlesion density inside the created macrolesion are reduced
in comparison to the static beam, but not significantly different. The median macrole-
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sion volumes resulting from square and Gaussian modulations are 65.6 µL and 40.3
µL respectively, and the median lesion densities are 16.8% and 14.4%.
The pulse modulation groups corresponding to square and Gaussian profile are
shown in Figure 3.2. In the simulation modeling, the volume exposed by negative
pressures greater than 2 MPa, and marked by circles, were integrated across space
and time yielding 4.5 and 2.7 µL ·s for square and Gaussian modulation, respectively.
Figure 3.10: Example microscopic brightfield images of treated heart slices. The his-
tology slice (a) contains sparse microlesions. Note that microlesions
appear with a light blue stained by Evans blue. The shown histology
violates the standard heart model shown in (b). Distributed myocytes
are lying in different tissue layers and with varying orientations.
3.4 Discussion
The quantitative results generated by the previously developed and here tested
computer-aided scheme provide possibilities for numeric and quantitative 3D lesion
analysis and their dependence on experimental parameters that were investigated for
their relevance for developing and improving MCET.
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3.4.1 Cardiomyocyte Scoring
Visual lesion counting, as a traditional evaluation method, is appropriate for low
lesion count cases as discussed for Figure 3.4. However, for therapeutic applications,
a large number of lesions require tedious counting. The computer-aided scheme (Zhu
et al., 2015a) provides for an objective and quantitative lesion analysis. As shown in
Figure 3.4, a dramatic change in visual score versus auto score for high-count cases
opposed to low-count cases reveals the limitation of visual scoring, when counting
large numbers of lesions. Machine operated and tested algorithms prevail. Note that
even at low counts, auto score has a positively correlated relationship to visual score
but does not have a one-to-one correspondence. Variance arises from manual bias
differentiating individual cells from a clustered cell pool. On the other side as for
auto scoring, imperfection exists when a constant conversion factor is employed for
converting microlesion area, i.e. image pixels, on a given histology slide to a fixed
number of cells, eq. 1. An additional limitation is the assumption that cells possessing
the same dimensions for each heart layer but different orientations for three layers
(Zhu et al., 2015a). Our model uses a statistical average based on a standard heart.
This might lead to partial violations when the actual geometry (Figure 3.11 (a))
differs from the standard heart (Figure 3.11 (b)).
3.4.2 Experimental Perturbations Exclusions
Initially, the choice of injections sites, i.e. the jugular vein versus the tail vein,
were thought to possibly influence the number of systemically circulating microbub-
bles. Comparing the two cohorts, however, showed that the two microbubble admin-
istration routes were equivalent. As shown in Figure 3.12, tail vein (A) versus jugular
vein (B) injection did not lead to significant differences in the subsequent lesion for-
mation in either lesion density or in macrolesion volume. Additionally, variations
of transducer aiming were tested. Intentionally aiming ultrasound at ribs (Group C)
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Figure 3.11: Treatment impact for square and Gaussian pulse modulation schemes.
Results for the impact of individual focal treatment (group B) versus a
swept beam (group D) are shown for (a) the corresponding macrolesion
volume and (b) the observed lesion density. Similar impact is seen be-
tween Gaussian modulation and square modulation, which validates that
a swept beam scheme might be a viable method to shorten treatment
duration.
56
does not impact the therapeutic result. In vivo variations can be significant (see error
bars in Figure 3.12); however, there is significant overlap between the tested routes
for injection and between various aiming paths.
3.4.3 Acoustic Field Modeling
3.4.3.1 Acoustic Amplitude
Acoustic modeling provides a way to approximate lesion formation. In the ther-
apy, impact analysis bioeffects of various acoustic exposures were investigated. The
associated field simulation underestimates the mean radius of the macrolesion at 4
MPa as shown in Figure 3.6 (c). This is because in vivo some of the beam penetrates
the left ventricle. This part of the beam was not excluded in the simulation, thus the
simulation resulted in averaging out the affected macrolesion radius. Another factor
contributing to the greater treatment effect seen in vivo than the simulation comes
from deformation of hearts after being harvested. Rats were treated at the ends of
systole but hearts were relaxed after being sacrificed. Thus the acoustic pattern may
be distorted to some extent.
3.4.3.2 Swept Beam
Treatment in humans will require focusing of the therapeutic beam at a larger
area than currently done in rodents (rats). Such will either lead to the need of a
modified, i.e. larger, point spread function or more likely numerous repetitions of
individual exposures. The latter can be realized by either individual focal treatments
or by employing a swept beam. The former will require a longer time for treatment of
an equivalent total count of focal spots since the beam will be stepped from treatment
location n to n+1., therefore a swept beam was investigated. Illustrated by O plot
marks in Figure 3.2, are the individual tone bursts that exceed the lesion formation
pressure threshold. With that and the previously mentioned axisymmetric rotational
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Figure 3.12: Comparison of treatment impact for different injections sites and ul-
trasound aiming strategies. Results show (a) macrolesion volume (b)
and lesion density for two microbubble administration routes, i.e. tail
vein (A) versus jugular vein (B) injection; additionally shown are (c)
macrolesion volume and (d) lesion density for regular aiming (B) and
intentionally aiming at ribs (C). Injection and aiming variations do not
significantly differ among the tested groups.
58
model (point spread function), an effective treatment volume was simulated. Inte-
gration across space and time, yielded 4.5 and 2.7 µL · s for square and Gaussian
modulation, respectively. Therefore the swept beam simulation predicts an effective
volume of 59.8% of that of an individual focal treatment. The experimental macrole-
sion volume shown in Figure 3.10 (a) yields an effective median volume fraction of
61.5%, supporting the axisymmetric rotational volumetric model.
3.4.4 Thresholded Induced and Statistically Accumulated Lesion
3.4.4.1 Lesion Formation as Accumulated Statistical Events
In the experiment of increasing infusion, the slightly decreasing trend of lesion
density shown in Figure 3.6 may indicate some shadowing effect caused by a large
population of instantaneous microbubbles placed along the beam path, acting as
scatterers. However, the shadowing factor will need to be verified for the cases of a
longer path, such as in a larger animal model.
The experiment of various infusion durations of contrast agents is potentially
equivalent with longer duration exposure. As shown in Figure 3.13, visual score, mi-
crolesion volume, macrolesion volume and mean radius of macrolesion showing posi-
tive correlation revealing the fact that the probability to create lesion is accumulated
over time. Growth of the macrolesion radius indicates that the edge of the macrole-
sion is contributing to the lesion formation over time. Lesion density increases for
longer infusion times. Short term and intermediate do not significantly differ. This
could be due to the lack of statistical power or too short of a duration to allow for fully
developed statistical analysis. The macrolesion lengths are not showing any strong
correlation with the infusion interval, as they are likely limited by the distal ventricle
and possibly due to tissue attenuation.
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Figure 3.13: Scatter plot of characterized parameters versus infusion durations. Re-
sults for (a) visual score, (b) microlesion volume, (c) macrolesion volume
and (d) macrolesion mean radius show some linear dependence with re-
spect to infusion duration, revealing the fact that the probability to cre-
ate lesion is accumulative over time. Growth of the macrolesion radius
indicates that the macrolesion edges contribute to the lesion formation
as well.
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3.4.4.2 Microlesion Density versus Ultrasound Amplitude
Least square fitting in Figure 3.7 (a) implies that an increasing acoustic pressure
has a positive effect on microlesion formation up to 4 MPa, i.e. higher acoustic pres-
sure or exposure possesses the higher potential to induce bioeffects. A similar positive
correlation of acoustic amplitude on cavitation-induced bioeffects was also presented
by Samuel et al. (Samuel et al., 2009). One possible reason is that larger pressure
will result in a larger active microbubble population. Therefore a larger density of
microlesion will be induced by the then more frequent microbubble cavitation events.
For a constant pressure amplitude, macrolesions also grow radially over time. This
is because of the probabilistic accumulation of microlesions on the penumbra of the
current macrolesion. There the probability for microlesion generation is larger than
zero percent and smaller than one hundred percent, i.e. the sound pressure amplitude
is close to the threshold pL discussed above. If is 20%, then a 5-times longer exposure
will statistically result in additional lesion formation.
3.4.4.3 Acoustic Pressure Threshold
The zero microlesion volume shown in the line fit in Figure 3.7 (b) might overesti-
mate the acoustic pressure threshold for lesion induction. This is because microlesion
volumes were characterized in a way that could bias towards beam regions with lower
acoustic pressure and hence lower partial microlesion volume.
Additionally, the acoustic pressure threshold for microlesion induction by either
lesion densities or microlesion volumes, is a rough estimation and may be inaccurate
due to biological variations, with R2 being 0.48 and 0.56.
3.4.5 Application in Human
Ideally, the wanted axial length of the transducers point spread function matches
the myocardial thickness. Here in the presented small animal model, a shorter depth
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of field would have been desirable, though no side effects for here 1 day acute studies,
except for some pulmonary hemorrhaging, presented in the study. The characterized
macrolesions for all rats showed similar lengths, which in most cases here is due
to the acoustic path restrained by the limited thickness of the left vertical wall.
However, when the study moves to a larger animal model (such as swine) rather
than the currently employed rodents (rats), the effect of therapeutic pressure on the
macrolesion length will manifest itself and be vital for lesion formation and accretion.
The shown results serve as a preliminary test of MCET for application in hu-
mans. The main benefit from this therapy method is the minimal invasiveness and
the hypothesis that cavitation-induced, sparsely distributed microlesions dont lead
to major infarct-like scars, which can disrupt conduction pathways and lead to heart
block, such as for alcohol ablation treatment (Folkert et al., 2010). The relationship
between lesion characteristics from the small animal model, such as lesion dimension
and density, and in situ ultrasound field, is assumed to be analogous to that of a large
animal model. Both models follow the same rationale of lesion formation. In the larger
model, especially in humans it is anticipated that we will have to create composite
lesions, i.e. lesions created by electronically and/or mechanically sweeping the beam.
For therapy of large volumes, the therapy beam will likely be scanned through the
desired volume (simulated here by the Gaussian modulation) to accomplish the treat-
ment in less time than is needed to treat point by point (as in high intensity focused
ultrasound (HIFU)). Suppose a human subject needs MCET treatment at a myocar-
dial region of 4 cm diameter (Maron, 2005). Assuming that the left ventricular wall
of the hypertrophic heart has a 21 mm thickness (Maron et al., 2003b), a macrolesion,
approximated as a cylinder, with volume pi × (4cm/2)2 × 21mm = 28.4mL, would
be needed. Assuming the therapy employs the recommended dose of Definity R© for
diagnostic exams, i.e. 5µL/kg/min, a five-minute treatment of a single focal spot
will yield a 50 µL macrolesion with 20% microlesion density. To create the aforemen-
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tioned macrolesion, a total duration of approximately 2,640 minutes will be needed to
achieve the desired lesion volume. Recruitment of a swept beam to foster the lateral
lesion formation at 56 fps, as discussed above, will reduce the total duration to 47
minutes. Stacking multiple axial focal zones will enlarge axial lesion size and further
accelerate the therapy. The above calculations are under the assumption that the in
vivo microbubble distribution in the myocardium is similar in human and the chosen
rat model. A large animal model for human cardiophysiology, such as swine, will be
needed for investigating the clinical transition for MCET.
3.5 Conclusion
The quantitative scoring scheme overcomes the limitation of traditional visual
scoring and works for histological cases with a large lesion count, i.e. has an appro-
priate dynamic range for evaluating therapeutic applications. The presented results
have shown that MCET-induced macrolesions grow radially as the acoustic pressure
amplitude increases. A swept beam as a new method to shorten treatment time seems
promising but requires additional verification to ensure efficacy. These characteriza-
tions and validations may assist future MCET treatment planning.
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CHAPTER IV
Chronic Effect Evaluation of MCET
4.1 Introduction
Currently available clinical methods for myocardial reduction in treating Hyper-
trophic Cardiomyopathy (HCM) are debulking of the myocardium. The primary
method for reduction of asymmetric septal hypertrophy with perturbation of the mi-
tral valve leaflets, surgical septal myectomy, is largely invasive(Maron et al., 2003a;
Gersh et al., 2011). Alternatives to surgery have been sought using various tech-
nologies, such as thermal ablation using ultrasound (Otsuka et al., 2007) or radio-
frequency ablation (Lawrenz et al., 2011), alcohol septal ablation (Gersh et al., 2011;
Leonardi et al., 2010) and so on. To date, these techniques are not widely used due
to their limitations and potential adverse consequences, e.g. a need for pacemaker
implantation in 21% of patients (Lawrenz et al., 2011).
We have developed a novel ultrasonic technique called Myocardial Cavitation-
Enabled Therapy (MCET), which aims to shrink the targeted myocardium over time
after noninvasive treatment. The treatment involves intermittent pulsed ultrasound
(higher than normal diagnostic pressures, (Miller et al., 2015)) together with ultra-
sound contrast-agent microbubbles to generate cavitation and tissue injury in the
myocardium. This treatment produces scattered sites of ultrasound-induced injury,
so called microlesions, only in the volume of interest. The target volume can be
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manipulated by focusing ultrasound and is defined as a macrolesion. In previous
acute animal studies, characterized MCET lesion creation (Zhu et al., 2015a) was
dose-dependent, adjustable by manipulation of the ultrasound focus, optimized at
the end of systole, could be monitored by premature ventricular complex frequency,
and the degree of injury correlated with troponin levels (Miller et al., 2014a,b, 2015;
Zhu et al., 2015b). However, the extent of tissue shrinkage as the final goal remains
to be addressed.
This chapter focuses on the long-term effect evaluation of the myocardium af-
ter MCET to verify the central hypothesis, i.e. myocardial reduction. With the
computer-aided histological scheme, the fraction of myocardial tissue destroyed and
the resulting scar formation, along with the extent of tissue shrinkage were evaluated.
4.2 Methods and Materials
4.2.1 Animal and Tissue Preparation
Tissue samples were collected and prepared for histological evaluation 6 weeks af-
ter treatment. Briefly, in vivo acute operations were conducted under ketamin/zylazine
IP anesthesia on Dahl SS rats (Charles River, Wilmington, MA, USA) and SS-16BN
rats (Medical College of Wisconsin, Milwaukee WI) under the approval and guid-
ance of the Institutional Animal Care and Use Committee. All rats in the treated
group were infused with an in-house developed closely duplicate of the ultrasound
contrast agent Definity R© (Lantheus Medical Imaging, Inc., N. Billerica, MA), as de-
scribed previously (Lu et al., 2016; Miller et al., 2016), at a rate of 5 µL/kg/min
(tail vein catheter). MCET was acoustically facilitated with a 1.9 cm diameter and
3.8 cm focus single element transducer transducer, aimed in vivo using a co-aligned
cardiac phased array (10S, Vivid 7, GE Healthcare) to focus approximately 0.5 cm
into the myocardium as illustrated in Figure 4.1 (Miller et al., 2014a). For therapy,
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5 or 10-cycle tone bursts at 1.5 MHz, 16 repetitions of peak rarefactional pressure
amplitude (PRPA) above 4 MPa at a 0.25 ms pulse interval, i.e. 4.0 kHz pulse rep-
etition frequency (PRF), were sent. Ultrasound exposures, modulated by a square
or Gaussian function (Lu et al., 2016), were triggered every 4 or 8 heartbeats, at
end-systole (RR/3, using ECG gating), and lasted for 5 or 10 minutes. The rat sham
group was exposed using either set of parameters for 5 or 10 min without infusion of
contrast agent, followed by 5 or 10 min infusion of contrast agent with no ultrasound
exposure. Long-term follow-up was undertaken to assess treatment outcomes with no
adjuvant, losartan or methylprednisolone (MP). The use of methylprednisolone and
losartan as adjuvants intended to reduce the acute inflammatory response (Roberts
et al., 1985) and subsequent scar formation (Frimm et al., 1997). A high dose of 30
mg/kg MP or low dose of 1 mg/kg given at therapy and at 3, 6 and 24 hr post therapy
were utilized. Losartan was dosed at 10 mg/kg/day by gavage starting one day after
ultrasound treatment and continuing for 4 wks.
At the end of wk 6, the hearts were removed. After cannulation of the aortas,
the hearts were immersed in formalin after being connected to a column of neutral
buffered formalin set to a height equivalent to a pressure of 15 mm Hg (20 cm H2O).
In this way, the hearts were fixed approximately in an end-diastolic configuration
(Whittaker and Patterson, 2000). Each heart was cut parallel to the atrioventricular
groove into four or five slices. For each rat, one slice that included the most treatment
area was processed at the Histology Core of the University of Michigan Dental School
with Massons trichrome staining to show fibrosis.
4.2.2 Microscope Image Acquisition
Brightfield microscopic images were obtained for each tissue-section through a mi-
croscope camera system (SPOT Flex, Diagnostic Instruments, Inc., Sterling Heights,
MI, USA) with a high resolution and large field of view objective (Leica Plan APO
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Figure 4.1: Schematic of the positioning setup of the imaging probe and the thera-
peutic transducer. For targeting, the rat heart was located at 2.25-cm
depth at the edge of the sector, as illustrated on the left. Subsequently,
the therapeutic transducer was moved in so that the beam followed the
same path (dotted gray line) as the previously identified image line (solid
gray line), as illustrated on the right. The heart was right in the focal
zone of the therapeutic transducer (3.8-cm focal length), as illustrated
at the center of the image sector at 2.75-cm depth (dashed gray line).
The solid black arrow line on the left side indicates the movement of the






































































































































































































































































































































































































1.6x, Leica Microsystems, Ltd., Heerbrugg, Switzerland). The images were acquired
as 16 bit 4,096 by 4,096 pixel, RGB, covering the entire tissue sections. Three im-
age sets of sham, moderately treated and severely treated, respectively, are shown as
an example in Figure 4.2. The upper row are photographs of the harvested hearts,
the middle row are corresponding microscopic Massons-stained images used in im-
age processing for analysis with the third row being zoomed in for the fibrous region
for better illustration. The tissue fibrosis was evident in Massons trichrome-stained
slides. Blue-stained areas (collagen) were indicative of fibrosis formation in the lesion
areas relative to the red background tissue.
4.2.3 Image Processing for Quantitative Analysis
As illustrated in Figure 4.3, tissue detection was done first to set boundaries
for fibrosis analysis and form the base for myocardium wall thickness measurement.
After fibrosis detection, the region affected by the therapeutic beam was estimated.
Fibrosis density was measured within the region, which also served as an objective
segment of the heart wall for thickness measurements. Radially measured heart wall
thickness measurements were enabled by the morphologic information of the heart
from the tissue mask.
Tissue detection: The main objective in this step is to segment the tissue portion
based on morphologic information from brightfield images to constrain the subsequent
characterization. This is similar to the tissue detection technique involved in (Zhu
et al., 2015a), except that RGB images were transformed to gray scale, which is less
computationally expensive without sacrificing spatial information. Gray scale images
were downsampled first to be segmented and then upsampled back after segmentation
to decrease computational load. A threshold mask and an edge-detected mask were
obtained simultaneously from a normalized brightfield image, which was then fused
together yielding the tissue mask.
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Figure 4.2: Example photographs and microscopic images for Massons trichrome-
stained hislotogical slices, from left to right columns for groups sham,
A and B, and top to bottom for heart photograph, microscopic image be-
ing processed and zoomed sections revealing Massons trichrome-stained
cells respectively. Upper row: 1x magnification photographs taken 6 wk
after exposure. Bar = 1 mm. Middle row: 1x magnification brightfield
images of Massons-stained slices, used in image processing for analysis;
arrow points to possible tissue shrinkage within damaged area. Bar = 1
mm. Lower row: 103 magnification brightfield images of Massons-stained
slides. Bar =100 µm. (Lu et al., 2016)
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Figure 4.3: Flow chart of image processing for measurements. Tissue detection was
done first to set boundaries for fibrosis analysis and form the base for
myocardium wall thickness measurement. After fibrosis detection, the re-
gion affected by the therapeutic beam was estimated. Fibrosis density was
measured within the region, which also served as an objective segment of
the heart wall for thickness measurements. Radially measured heart wall
thickness measurements were enabled by the morphologic information of
the heart from the tissue mask.
Fibrosis detection: The original images of RGB color space were converted to
Lab color space (Hunter , 1958, 1948). The Lab color space discribes mathematically
all perceivable colors in the three dimensions with L for lightness and a and b for
the color-opponents, green-red and blue-yellow. Since the lightness of the images are
not interesting for tissue characterization, this dimension was eliminated. Only pix-
els within heart region were fed into the fibrosis detection. Pixel values in the two
dimensions ‘ab’, were clustered by the k-means algorithm into 2 groups indicating
fibrosis (blue) and normal tissue (red) based on Euclidean distance. K-means cluster-
ing, partitions observations, here observations as color vectors of the two dimensions
‘ab’, into k (here is the 2 color groups of fibrosis and normal tissue) clusters in which
each observation belongs to the cluster with the nearest mean, serving as a prototype
of the cluster. After k-means clustering iterated 3 times, to avoid local minima, the
fibrosis mask was formed. An example is shown in Figure 4.5. The treatment target
region was estimated from the centroid of the populated fibrosis with a 3 mm win-
dow as shown in Figure 4.4, which was estimated from acute lesion characterization
(Zhu et al., 2015a). Fibrosis fraction was then obtained by measuring the fraction of
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fibrotic tissue in this treated region.
Figure 4.4: Quantification of the fibrotic tissue fraction within the treatment volume
in Massons-stained slides. Transparent regions are the most dense lesion
cloud ventricular wall regions where densities were calculated. Those
regions are constrained by a 3 mm wide window. Left: group A, right:
group B. Bar = 1 mm. (Lu et al., 2016)
Heart wall thickness measurement: Based on the tissue mask, the heart wall
thickness was measured radially from the left ventricular centroid. The thickness was
defined by the distance from the left ventricular wall boundary to the other tissue
being either the outer heart boundary or the septal wall boundary, whichever is closer,
as indicated as line segments in the top left Figure 4.6. Quite often, sections were
cut slightly oblique cut, resulting in an elliptical shape, for which the wall thickness
was increased at the major axis ends of the ellipse. Therefore, an ellipse was fitted
to the left ventricle. The measurements were corrected by normalizing the thickness
measurements to the minor axis thickness as shown in bottom Figure 4.6. Finally the
wall thickness evaluated for the treated region defined from fibrosis detection could
be objectively quantified.
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Figure 4.5: Example images illustrating fibrosis detection, from left to right columns
for original and zoomed in images, and top to bottom for heart pho-
tograph, 1x magnification brightfield images of Massons-stained slices,
tissue segment fed into k-means clustering and detected fibrosis, respec-
tively.
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Figure 4.6: Example images illustrating the process of heart wall thickness measure-
ment. Top left: the thickness was defined by distance from left ventricular
wall boundary to another tissue boundary, being either the outer heart
boundary or the septal wall boundary, whichever is closer, as indicated as
line segments. Top right: the wall thickness was evaluated for the treated
region defined from fibrosis detection. Bottom: wall thickness was mea-
sured radially from the center of the left ventricle centroid, corrected by
normalizing the thickness measurements to the minor axis of the ellipse
fitted to the left ventricle centroid.
74
4.3 Results and Discussion
The results for fibrosis fraction and left ventricular wall thickness centered at the
region of fibrosis are summerizd in Table 4.1 for various treatment conditions. Long-
term studies for healing process and maturation of the myocardium treated with
MCET to assess the potential therapeutic effect (Lu et al., 2016) were planned in
Group A and B. The objective of Group C to H was to evaluate adjuvant treatment
effect of the steroid MP and Losartan, in terms of inhibition of fibrous tissue formation
during the long-term healing process to achieve final muscle wall reduction.
4.3.1 Lesion Maturation
The quantified fibrosis fraction within the treatment volume indicates the fraction
of cardiomyocyte removal, which is much higher in group B than in group A (34±11%
vs. 9±6%, p < 0.001). The two sets of enhanced therapeutic parameters were used to
induce injury in rat hearts and to test the long-term outcome and tolerance of MCET.
Increased trigger intervals (from 1:4 to 1:8) and pulse durations (from 5 to 10 cycles)
induced more damage (Miller et al., 2014a). Moreover, square envelope modulation
at the highest PRPA had a larger effective macrolesion volume in terms of integrated
refractional pressure over time, compared with the Gaussian modulation (Zhu et al.,
2015b). On the basis of these findings, we chose a set of parameters with higher effect
(pulse duration of 10 cycles, 4-ms square modulation, 1:8 trigger for 10 min) and
another with lower effect (pulse duration of 5 cycles, 15-ms Gaussian modulation, 1:4
trigger for 5 min). The difference between the two groups illustrates the range of
therapeutic impact that can be achieved by respective exposure parameter selection.
As expected, higher exposure used in group B yielded more substantial injury than
lower exposure in group A. This was confirmed by the extent of fibrosis after 6 wks.
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4.3.2 Adjuvant Treatment
A preliminary chronic test was conducted in the Groups C-E to assess the utility
of losartan and low dose MP as adjuvants to reduce the long-term scar formation
in the treated region. The fraction of scar formation in the treated region was not
affected significantly by the initial low dose MP dosing nor, by the follow-up losartan
treatment. Nevertheless, both low dose MP and losartan were included in the chronic
study with the HCM-model rats in Groups F-H based on the toleration of the treat-
ments and the earlier published findings (Frimm et al., 1997; Roberts et al., 1985).
Group F and G were analyzed separately though the acute treatments were performed
the same way due to their significantly different responses to the therapy, premature
complexes in the ECG generation and troponin release (Miller et al., 2011). Group
G showed substantial fraction of fibrotic scar area at 42% in the treatment region,
and wall shrinkage of 2.29 mm compared to 2.74 mm in sham Group H.
4.3.3 Discussion
Massons trichrome staining revealed that up to 49% tissue in the center of the
treated area was involved in fibrotic lesions. The lesions were scattered and randomly
distributed in the anterior wall without gross tissue structure destruction. This may
be less severe for the tissue reduction in the treatment of HCM with fewer side ef-
fects, compared with traditional invasive septal reduction. Although the percentage
of tissue damage is substantial for Group B, no obvious shrinkage of wall thickness
was observed when measured with echocardiography. No consistent difference in wall
thickness among sham, A and B groups was found on histology 6 wks after treatment,
although some indications of wall thinning were noted in the high-exposure group.
The unevenness and variation of the left ventricular wall thickness in the histologic
sections preclude the identification and measurement of small changes in wall thick-
ness. However, the study with adjuvant treatment demonstrated a significant and
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therapeutically useful magnitude of tissue reduction observable histology (16%) rel-
ative to sham. Damaged microlesion areas seemed to be almost completely replaced
by fibrotic tissue formation following the acute inflammation after cavitation-induced
injury. This is characteristic of the normal replacement process in which fibrosis and
scar preserve the structural integrity of the heart, for example, after ischemic injury
(Baroldi , 1975). The inflammation and replacement scar volume seen here may be
amenable to pharmaceutical intervention. For comparison, in human HCM patients
with surgical myectomy, the interventricular wall thickness was reduced by 18% from
19.4 to 15.9 mm (Brown et al., 2011).
4.4 Conclusion
Here, with quantitative measurements of the fibrotic tissue fraction and heart mus-
cle wall change induced by MCET after a long-term healing process, we believe we
have demonstrated that MCET is promising as a minimally invasive myocardial tissue
reduction addition to HCM treatment options. We have presented ultrasound my-
ocardial cavitation enabled treatment as an image-guided method capable of graded
and diffuse tissue reduction with potentially minimal adverse side effects, relative
to alcohol ablation or other methods. We have shown that the MCET method can
be improved by addition of adjuvant treatment with steroid and antifibrotic med-
ication. The chronic study in the SS-16BN rat model of HCM has shown that the
MCET method is able to significantly reduce wall thickness by about 16%, which is of
therapeutically useful magnitude. After further development and refinement, MCET
treatment for HCM could fill the need for a new treatment option.
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CHAPTER V
Development of Monitoring Cavitation as
Treatment Feedback
5.1 Introduction
Hypertrophic cardiomyopathy (HCM) occurring in 1 of 500 people can lead to
sudden death to adults without prior indication (Maron and Maron, 2013). Echocar-
diography is one of the most common ways to diagnose hypertrophic cardiomyopa-
thy. Current treatment involves invasive and high-risk procedures such as surgery
or catheter-based ablation (Marian, 2009). A novel technique, named Myocardial
Cavitation-Enabled Therapy (MCET), was proposed as a means to achieve mini-
mally invasive myocardial reduction (Miller et al., 2014a). It has demonstrated the
possibility for shrinking targeted hypertrophic heart muscle over time without sub-
stantial scars (Lu et al., 2016). The treatment employs contrast echocardiography
at higher than diagnostic pressure amplitudes, to produce scattered microlesions (re-
gions of lethally injured cells) by introducing cavitating contrast agent microbubbles.
Previous studies of MCET have proven the efficacy of MCET to induce damage. The
micro-scale surgical impacts of local cardiomyocyte necrosis and microscopic lesions,
can accumulate with time to a desired total impact (Miller et al., 2014a,b, 2015; Zhu
et al., 2015a,b). Biological responses to the MCET, e.g. premature electrocardio-
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gram complexes from ECG (Miller et al., 2011), only serve as temporal qualitative
indicators for bioeffects. Other measurements, such as troponin levels and echocar-
diography (Miller et al., 2014a) right after treatment provide only the qualitative
information of the overall accumulated impact. A monitoring scheme for microbub-
ble cavitation during the treatment process is beneficial for treatment control, and a
spatial indicator is needed for localizing treatment effects.
Active ultrasound imaging of appearance change or presence of bubbles in the
medium has been incorporated in cavitation detection (Gateau et al., 2011). How-
ever, the imaging ultrasound pulses may interfere with cavitation signals resulting
in ambiguity of identifying cavitation. Passive acoustic imaging technique avoid this
by using an array to passively record cavitation emissions followed by beamforming
of the recordings to estimate the distribution of cavitating sources, and as such, al-
low real-time spatiotemporal monitoring of cavitation activity in the field of view
of an ultrasound transducer. Passive imaging in 2D has been proven to outperform
B-mode in accessing HIFU ablation (Jensen et al., 2012), and also been extended
to 3D (Collin et al., 2013). Its feasibility was verified with magnetic microbubbles
(Crake et al., 2015) and for short pulse insonations as well (Haworth et al., 2012).
Synchronization of the cavitation inducing transducer with the imaging transducer
provides better axial resolution. Microbubble cavitation imaging for sonothromboly-
sis was demonstrated using a single probe (Vignon et al., 2013). Pulse sequences were
designed as ultrafast imaging, interleaving destruction pulse and passive cavitation
detection interval to monitor bubble activities (Xu et al., 2014).
This chapter discusses several possible schemes for monitoring microbubble cav-
itation for MCET including quantification and imaging, which will assist future in
vivo studies for real-time temporal and spatial detection of microlesion formation.
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5.2 Methods and Materials
5.2.1 Linear Scatters vs. Microbubbles
5.2.1.1 Experimental Setup A: Separate HIFU and Receive
Microbubbles, ultrasound contrast agent (USCA) of Definity (Lantheus Med.
Imag., Billerica, MA), were diluted into phosphor buffered saline (PBS, pH=5.0)
and pumped at a maximum velocity of 4 cm/s in a 1.5 cm diameter thin walled dial-
ysis tubing setup. Polystyrene spheres of 5 µm diameter (2005ATS, Duke Scientific,
Palo Alto, CA) as linear scatterers were diluted to 0.15 g/1100 mL in a water and
glycerol suspension, to compensate for the larger mass density of the spheres relative
to PBS. Spectral data from the linear scatterers was compared to that of USCA for
compensating the system transfer function.
A preclinical ultrasound imaging system with a single element high intensity focused
ultrasound (HIFU) transducer, synchronization and a receive-only imaging array has
been implemented on a research platform (Verasonics Inc., Redmond, WA). ). Single
element transducers A314S (Panametrics, MA) and A381S (Panametrics, MA) at 1.0
MHz were driven in burst mode at 3.5 MHz, respectively serving as the HIFU trans-
ducer with focal lengths both of 3.8 cm. The HIFU transducer was operated at a pulse
repetition frequency (PRF) of 22 Hz with ten-cycle burst and with a peak-to-peak
acoustic pressure of up to 5.5 MPa at its focus. A 128-element linear array (L7-4,
ATL, Seattle, WA) was employed in receive-only mode. Then the HIFU transducer
was fired with its focus in the center of the dialysis tube. The L7-4 imaging array was
used as a passive cavitation detector and was placed at an angle of 32 degrees with
respect to the acoustic axis of the HIFU transducer. Therefore the imaging plane
becomes an ellipse instead of a circle as illustrated in Figure 5.1.
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Figure 5.1: The HIFU transducer was fired with its focus in the center of a thin walled
dialysis tube. The imaging array used as a passive cavitation detector and
placed at an angle of 32 degrees with respect to the acoustic axis of the
HIFU transducer.
5.2.1.2 Signal Processing Algorithm
A cavitation mapping technique (Vignon et al., 2013) was employed to spatially
localize and depict microbubble activity during HIFU exposure, and ready to be used
during treatment and to monitor microlesioning in vivo in real-time. The acoustic
emissions and scattered radio frequency (RF) signal from the volume of interest was
beam-formed by a delay-and-sum algorithm followed by signal maximum hold after
filtering f0 (the driving frequency) and 2× f0. The resulting so-called non-harmonic
frequencies exclude fundamental and harmonic as shown in Figure 5.2, and thus give
strong evidence of any cavitation activity. Beamforming on this filtered signal yields
spatial mapping of cavitation.
5.2.2 Microbubble Cavitation Detection
As described in section 1.2.1, there are two types of cavitation, stable cavitation
and inertial cavitation. Detection of emissions at the subharmonic (one-half the
driving frequency, f0/2, where m is an integer and f0 is 1.5 MHz) and ultraharmonic
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Figure 5.2: (a) Frequency spectrum of passively detected raw RF signals, (b) filtered
non-harmonic spectrum for subsequent beamforming. (Zhu et al., 2017)
(odd harmonics of the subharmonic, (2m + 1) × f0
2
) bands the inharmonic bands is
an indication of stable cavitation within an insonified bubble population. Inertial
cavitation results in substantial broadband emissions (Haworth et al., 2012).
5.2.2.1 Experimental Setup B: Combined HIFU and Receive
The experimental setup is similar to that described in section 5.2.1.1 with some
modifications, as provided next. A Definity R© substitute was employed as USCA,
diluted into phosphor buffered saline (PBS, pH=5.0) and pumped into a 1.5 cm
diameter dialysis tubing setup. Microbuble vials were activated at room temperature,
using a 45-s activation cycle. As the kinetic energy of the shaking results in heating
the fluid, the vials were allowed to return to room temperature over 60 min. The
agent was diluted by factors of 100, 200, 400, 800 and 1600 by volume into saline to
achieve a number density of approximately 8× 104 USCA/mL for 1:100 dilution.
Flow was maintained at 50 mL/min with a pump (model 77200-62, Masterflex,
Gelsenkirchen, Germany) in continuous withdrawal mode. A 96-element phased array
(P4-1, ATL, Seattle, WA) operated on a Verasonics platform serving as both HIFU
output transducer and receiving passive imaging transducer, like in regular pulse-echo
imaging mode. Thus, one acquisition involves RF traces from 96 receiving channels.
The HIFU transducer P4-1 was operated at a 1.5 MHz center frequency, 2 Hz duty
cycle, firing a ten-cycle tone burst at a 4kHz PRF for 20 repetitions. Ultrasound beam
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was focused at 7 cm away in the center of the dialysis tube. The imaging plane of
the array was placed perpendicular to the tube. This setup assures the microbubbles
replenish at 2 Hz but remain almost at steady state within the focal volume during
the firing of the 20 pulses.
Acoustic pressures (peak rarefactional pressure amplitude (PRPA) of 0.48 - 4.4
MPa in 18 increments, for various microbubble concentrations) were cycled through
ten times, randomizing the order of excitation pressures at the beginning of each
cycle, yielding ten excitations at each acoustic pressure per data set. The experiments
were performed with 40 measurements per exposure parameter (USCA concentration,
acoustic pressure) for averaging.
5.2.2.2 Cavitation Detection Processing
Scattering from the tube walls dominated the passively received signal. Received
signals from degassed water were used to estimate tubing walls in the time domain,
and a Hamming window was applied between tube walls to extract signals only within
the tube for each channel out of the total of 96. To eliminate acoustic clutter from
non-bubble scattering and compensate for the system transfer function, power spectra
from saline controls were subtracted from USCA power spectra in the frequency
domain.
Cavitation detection was performed based on power spectra of received RF signals.
For each acquisition, an average spectrum, computed in MATLAB (MathWorks Inc.,
Natick, MA), was obtained across 96 channels. Here, as shaded spectrum indicated
in Figure 5.3 left, the power spectrum bands were summed over a 2-kHz bandwidth,
centered around each spectrum band of interest. Spectrum band center at 3f0/2 was
used as a signature for stable cavitation noted as UH (ultraharmonic), and the band
center at 2f0 was used an indicator for nonlinear propagation, noted as 2H (second
harmonic). Broadband signature, noted as BB (broadband), indicating inertial cav-
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itation, of the power spectrum were defined as the sum power for frequency bands





) and within a band width of 2 kHz, where n is a positive
integer larger than zero. These bands were chosen to include only the transducer
bandwidth of 1-4 MHz. Finally, 3f0/2, 2f0 and broadband signatures were obtained
by averaging across measurements.
Figure 5.3: Power spectrum and microbuble signatures against the sequential num-
ber pulse RF at PRPA of 4.3 MPa with microbubble concentration of
4 × 104/mL. Left: power spectrum for acquired RF number 1, 2, 4, 8,
16 and 20 pulse out of 20 pulses at 4 kHz for one firing with shaded
spectrum used for extracting bubble signatures. The spectrum band cen-
ter at 3f0/2 (red shading) was used as a signature for stable cavitation,
and the band center at 2f0 (green shading) was used an indicator for
non-linear propagation. Broadband signature (blue shading), indicating
inertial cavitation, of the power spectrum were defined as the sum power





) and within a band width
of 2 kHz, where n is an integer. These bands were chosen to only include
the transducer bandwidth of 1-4 MHz. Right: 3f0/2, 2f0, broadband
signatures plotted against the acquired RF pulse number 1-20. (Setup B)
5.2.3 Passive Cavitation Imaging
Passive cavitation imaging processes the cavitation emissions passively received
with an array to map emissions from an unknown location (Gyongy et al., 2008;
Salgaonkar et al., 2009; Farny et al., 2009).
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5.2.3.1 Imaging Algorithm
Passive cavitation imaging using a delay, sum, and integrate algorithm to beam-
form the acoustic emissions received on a passive array has been previously described
(Haworth et al., 2012). This algorithm is based on the assumption that signals orig-
inating from a single source and arriving at different elements of an array will be
coherent, though arriving at different times based on the time of flight from the
source to each individual element (Figure 5.5(a)). Figure 5.4 shows the relationship
between an image location ~x and the array. To form an image, the received signals
are individually temporally delayed based on the propagation times between the re-
ceiving elements and the spatial location that the pixel represents. The waveforms
are summed across the receiving elements and, due to their coherent nature, add con-
structively if the location of the pixel represents the source location (Figure 5.5(b)).
If the received signals are time delayed using propagation times to a location that is
far from the source, the waveforms will not add fully constructively (Figure 5.5(c)),
resulting in a lower amplitude and less energy. After summing over channels, the
frequency-dependent energy in the summed waveform was computed and used to
assign a pixel value at that location.
The frequency dependent image at location ~x, B(f, ~x), is defined in Equation 5.1,
where Sn(f) is the frequency domain representation of the signal received on the
nth element of the passive array located at ~xn







The pixel amplitude is determined from the energy (or power) of the interest for
certain frequency bands in the summed signal B(f, ~x). To form a complete image,
the energy at each desired pixel location is computed. The algorithm for computing
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where f1 and f2 define the lower and upper frequency band limits, respectively. Com-
posite images are useful when the bandwidth of interest is finite. Furthermore, in-
coherent noise will be reduced in this multifrequency composite images relative to a
single-frequency image.
Figure 5.4: Schematic of passive imaging array and corresponding imaging plane. The
nth element of the array is labeled and the black dot indicates pixel or
region of interest location ~x. The elevational direction is out of the plane
of the page. (Haworth et al., 2012)
5.2.3.2 Experimental Setup
Experiment C: Combined HIFU and Receive - To verify the feasibility of pas-
sive cavitation imaging in our system, the experiment to record data was set up
with a more confined microbubble ‘carrier’. The layout of the experiment is similar
to Figure 5.1 but instead of dialysis tubing, a one-way flow consisting of a micro-
polyurethane tubing (inner diameter-203 µm, outer diameter-356 µm, Catalog #
PE-8-25, Strategic Applications Incorporated, Libertyville, IL) was used to direct
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Figure 5.5: Schematic illustration of delay, sum, and integrate algorithm. (a) An
acoustic pulse is emitted from a point source (red circle). Solid blue lines:
wavefronts. Red dashed lines: acoustic propagation paths, each with a
corresponding time of flight. Black outlined rectangles: array elements.
The recorded waveforms for each element are shown as a single-cycle
pulse arriving at different times. (b) When ~x corresponds to the source
location and is used to compute the time delays to shift the waveforms, the
waveforms will sum constructively. (c) When ~x is a location away from the
source, the time-delayed waveforms do not fully add constructively and
the summed waveform has a lower amplitude and less energy. (Haworth
et al., 2016)
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the solution from the bottom of the reservoir through the region of insonification. A
phased array P4-1 was employed as both high intensity output transducer and passive
receiving one via the Verasonics system.
Experiment D: Separate HIFU and Receive - Another experiment system for val-
idation of passive imaging algorithm to identify multiple cavitating locations was
established. A 298-element, concentric array (Imasonic SA, Besancon, France) was
driven by an in-house high power system for therapeutic excitations. The phased
array P4-1 on Verasonics was operated on receive-only for cavitation detection and
B-mode imaging for aiming. A phantom with 3M iM30K Hi-Strength Glass Bubbles
(3M, St. Paul, MN) suspended in ultrasound gel was employed as the medium. The
HIFU system focuses at 12 cm away and fires 12 pulses at 4 kHz with 4 pulses at each
location being 5 mm apart as illustrated by hyperechogenicity in a B-mode image
recorded with the P4-1 in Figure 5.11 (a).
5.3 Results
5.3.1 Linear Scatters vs. Microbubbles Imaging
Results in this section are from Setup A. Acoustic emissions from USCA reached
from the fundamental to the 8th harmonic for a 1.0 MHz excitation and were de-
tectable within the bandwidth of the L7-4 for all tested dilutions (25 µL, 50 µL,
100 µL, 200 µL stock per liter saline). Ratios of higher harmonics to fundamental
frequency increased with drive pressure and exceeded 5 dB.
Results for excitation at 3.5 MHz center frequency are shown in Figure 5.6(a)(c)(e).
Three pressure levels were used. Acquisitions with higher acoustic pressure yielded
higher signal to noise ratios, that in turn were ascribed to more cavitation events. To
ensure that the detected signals were generated from the active agents rather than the
acoustic field, a set of control experiments were performed with polystyrene spheres.
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Results are shown in Figure 5.6(b)(d)(f).
No cavitation was detected with a low pressure excitation at 0.31 MPa of spheres,
shown in Figure 5.6(b). Greater contrast in beamformed images resulting for ex-
posure of USCA (Figure 5.6(a)(c)(e)) than images formed for polystyrene spheres
(Figure 5.6(b)(d)(f)) was assumed to provide evidence of the existence of microbub-
ble cavitation events.
At 2.8 MPa peak-to-peak pressure, USCA yielded a 5 dB higher signal compared to
polystyrene spheres (Figure 5.6(e)). Mapped cavitation signals were observed laterally
within 1.5 mm of the HIFU transducer focus and axially within approximately the
spatial pulse length of 4.5 mm as shown in Figure 5.7.
5.3.2 Microbubble Cavitation Detection
The results in this section are from Setup B presenting influences of microbubble
cavitation detection resulting from various 1) number of repetitive ultrasound pulses
2) ultrasound pressure amplitude 3) microbubble concentration, respectively.
5.3.2.1 Repetitive Ultrasound Pulses
One HIFU firing involves 20 repetitive pulses at 4 kHz. Figure 5.3 shows the
power spectrum of some representative pulses within one pulse series and cavitation
signatures plotted against the acquired RF pulse number 1-20. The decreasing trends
of bubble signatures reveal the destruction of microbubbles.
5.3.2.2 Pressure Dependence
Microbubble activity was investigated against acoustic pressure change for various
microbubble concentrations as shown in Figure 5.8 left. As acoustic power increases,
cavitation signatures from received signals for the first RF pulse out of 20 increases
until it saturates for increasing power. Energy for 2f0 clearly increases to a point
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Figure 5.6: Passive imaging results (Setup A) for 3.5 MHz excitation and acoustic
pressures of (a) (b) 0.31 MPa, (c) (d) 1.30 MPa (e) (f) 2.38 MPa for
contrast agent (a) (c) (e), and for polystyrene spheres (b) (d) (f) with
the red dotted ellipse delineating the imaging plane intersected with the
dialysis tube. (Zhu et al., 2017)
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Figure 5.7: The result (Setup A) for high acoustic pressure enables us to resolve a 5
dB difference between contrast agent and spheres. The spatial resolution
is 4.5 mm for axial and 1.5 mm laterally.
and starts to decrease, implying energy transition to other frequency components.
Signatures of broadband and 3f0/2 seem to keep increasing as acoustic power go up
for both bubble concentrations 2 × 104/mL and 4 × 104/mL. However, for bubble
concentration of 8 × 104/mL, broadband signature seems to saturate and decrease
after 2.7 MPa PRPA.
5.3.2.3 Microbubble Concentration Dependence
The cavitation signatures from received signals for the first RF pulse out of 20
were investigated against microbubble concentration for various acoustic pressures
as shown in Figure 5.8 right. The signatures increase reasonably as concentration
increases indicating more microbubble were acoustically active.
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Figure 5.8: Microbubble signatures from received signal for the first RF pulse out of 20
increases for acoustic variation and microbubble concentration variation.
Left: acoustic influence on microbubble signatures for various microbub-
ble concentrations. Right: influence of microbubble concentrations on
microbubble signatures for various acoustic pressure. (Setup B)
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5.3.3 Passive Cavitation Imaging
Broadband signals as described in section 5.2.2.2 were beamfored by passive cav-
itation imaging using Setup C.
5.3.3.1 Frequency-Domain Imaging
Passively beamformed image on broadband frequency components using frequency-
domain is shown in Figure 5.9, with 0.25 cm wide 6 dB lateral resolution and 5 cm
wide 6 dB axial resolution.
Figure 5.9: 2D (left), axial (middle) and lateral (right) cross-sections for passively
beamformed cavitation image. (Setup C)
A variation of frequency-domain passive cavitation algorithm demonstrated called
frequency-sum beamforming (H. Abadi et al., 2013), which employs second-order or
higher products of the acoustic emissions of Equation 5.1 to manufacture higher
frequencies, thereby reducing the size of the point spread function (PSF). Improved
resolution with frequency-sum algorithm beamformed at 2f0 (Equation 5.3 ) and 4f0
(Equation 5.4 ) has been seen using the same input data as shown in Figure 5.10.















Figure 5.10: Axial and lateral cross-sections images beamformed using the frequency-
sum algorithm at 2f0 (upper) and 4f0 (bottom). (Setup C)
5.3.3.2 Cavitation Location Imaging
Hyperechogenicity in B-mode imaging from P4-1 delineated cavitating locations
of the HIFU system using Setup D, as shown in Figure 5.11(a) with a overlaid zoom-in
window. Passive cavitation images were beamformed with the received signal shown
in a hot map overlaying the B-mode image for 1-4 RF pulses (Figure 5.11(b)), 5-8 RF
(Figure 5.11(c)) and 9-12 (Figure 5.11(d)) out of 12 pulses. The lateral resolution is
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The decreasing energy of cavitation signatures for repetitive ultrasound pulses
implies the penetration of ultrasound after destructing the microbubbles closer to the
transducer. Thus, the number of pulses needs to be taken into great consideration
to achieve a desired depth of effect, especially in larger animal models with acoustic
paths at higher attenuation.
With raising acoustic power, cavitation activities increase. The detected change in
microbubble signatures positively correlates with bubble concentration. This proved
the possibility of the employed system to detect and quantify larger than zero cav-
itation events. However, some low-level broadband emissions may also result from
stable cavitation, due to random bubble motion without inertial collapse, while some
subharmonic emissions may result from large-amplitude bubble oscillations preceding
inertial collapse (Haworth et al., 2012). Thus, variance of cavitation events quantified
by frequency contents may exist. Nevertheless, in MCET treatment monitoring, it
would be more interesting to relate detected signals to actual induced therapeutic
effects, e.g. microlesion distribution, rather than explicitly distinguishing between
stable and inertial cavitation.
5.4.2 Imaging Algorithm
The key difference between passive (as used in 5.2.3.1) and B-mode imaging (as
used in 5.2.1.2) is that the passive algorithm does not use the absolute time of flight
to determine the depth of the acoustic emission (Haworth et al., 2016).
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Figure 5.11: (a) B-mode image showing hyperechogenicity cavitating locations with
zoom-in window for (b)(c)(d). (b) Passive cavitation imaging (color)
overlaid on B-mode image for the 1-4 RF pulses out of 12 pulses. (c)
Passive cavitation imaging overlaid on B-mode image for the 5-8 RF
pulses out of 12 pulses. (d) Passive cavitation imaging overlaid on B-
mode image for the 9-12 RF pulses out of 12 pulses. (Setup D)
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The presented results were all beamformed in the frequency domain (Haworth
et al., 2012). A first glance, beamforming in the frequency-domain seems more com-
putationally expensive than in the time-domain for its necessity of performing Fourier
transform. However, there are several potential advantages for frequency-domain over
time-domain analysis (Haworth et al., 2016). Firstly, for the delay, sum, and integrate
method, when only some frequency bands of interest need to be beamformed, the com-
putational time compared is largely reduced than beamforming the entire bandwidth
(similar to the time-domain approach) (Arvanitis et al., 2015). Additionally, the fre-
quency content of cavitation emissions is often used to characterize cavitation to be
stable cavitation or inertial cavitation as discussed earlier. Operating in the frequency
domain makes frequency selection simpler and more direct than using time-domain fi-
nite impulse response filters. It is also more convenient to select and analyze multiple
discrete frequency bands for analysis simultaneously. Another aspect is the temporal
quantization error for delaying signals, which time-domain analysis suffers from due
to shifting discrete temporal samples. The temporal quantization error can lead to
grating lobe artifacts unless the received signals are sampled temporally at a very
high sampling rate (often tenfold or higher than the highest frequency of interest) or
the received samples are interpolated to approximate a high sampling rate. While in
the frequency domain, the time delays become phase shifts where the quantization
error is reduced to the floating-point precision.
While a good lateral resolution was presented, the unsatisfactory axial resolu-
tion is the major drawback of any passive cavitation imaging algorithm. The axial
resolution does not depend on the insonation pulse duration or shape but only the
frequency-dependent diffraction pattern of the array (Haworth et al., 2012). Other
prior information, or information detected from other sources, e.g. extra detector
may help to improve imaging resolution if allowed.
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5.5 Conclusion
The systems presented have shown the feasibility of microbubble cavitation detec-
tion, quantification and localization. Passive cavitation imaging algorithms provide
spatial information of cavitation events. The activities of bubble dynamics and cavi-
tation can be mapped in bench-top setups with a HIFU transducer and a receive-only
passive imaging array. The higher acoustic response from contrast agents compared
to that from polystyrene spheres in the reconstructed images suggests that cavitation
events undergoing inertial cavitation can be detected. Cavitation can be localized
with reasonable lateral spatial resolutions. The described passive imaging algorithm
applies to both systems: Verasonics alone transmitting HIFU and receiving, and Ve-
rasonics only for passive receiving with a HIFU system for therapeutic firing. The
overall therapy monitoring system is able to adequately delineate the spatial location
of triggered microbubble dynamics. Future work for MCET monitoring involves de-
velopment of a coefficient or transfer function relating cavitation signals to the extent
of induced microlesion, and feasible applications of cavitation imaging techniques for




6.1 Summary and Conclusions
6.1.1 Introduction
Hypertrophic cardiomyopathy (HCM) is one of the most common genetic cardio-
vascular diseases, occurring in 1 in 500 people (Maron et al., 2012). Septal and apical
hypertrophies leads to obstruction of the left ventricular outflow path in up to 75%
of patients. About one-third of patients with obstruction remain symptomatic af-
ter pharmacological therapy and are candidates for tissue debulking (Marian, 2009).
Two methods presently available are open heart surgery for septal myectomy and
transcatheter septal ablation with alcohol (Members et al., 2011). The less inva-
sive alcohol ablation procedure unfortunately has a high incidence of heart blockage
requiring permanent pacemaker and of arrhythmia associated with scarring, and is
not widely applied (Maron et al., 2003b). A completely new non-invasive option
for non-hypertensive, hypertrophic tissue debulking is sorely needed to avoid heart
transplants for HCM and avoid long-term effects of ablations and avoid surgery when
advisable.
Therapeutic ultrasound is a powerful modality that enables safe, low-cost and
non-invasive delivery of energy to targeted tissues located deep within the body for
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treatment (Crake et al., 2015). It is highly versatile and readily lends itself to a
diverse range of applications in the fields of minimally invasive surgery and targeted
drug delivery including thermal ablation (Illing et al., 2005), mechanical tissue erosion
(Roberts et al., 2006), blood clots breakdown (Molina et al., 2009) and drug and
gene delivery (Hernot and Klibanov , 2008). Acoustically active microbubbles are
routinely used to improve contrast in conventional ultrasound diagnostic imaging
(Schutt et al., 2003) and may also assist with therapeutic effects, in particular those
involving acoustic cavitation (Unger et al., 2002).
Myocardial contrast echocardiography (MCE) has enabled enhanced contrast in
visualization of myocardial perfusion. Using higher than diagnostic pressure ampli-
tudes in myocardial contrast echocardiography (MCE), Myocardial Contrast Enabled
Therapy (MCET), was proposed as a means to achieve minimally invasive myocardial
reduction (Miller et al., 2014a). The whole process is as illustrated in Figure 6.1. The
treatment employs intermittent ultrasound to destruct contrast microbubbles result-
ing in lethally injured scattered cells in the focal volume. The micro-scale surgical
impacts of local cardiomyocyte necrosis and microscopic lesions, can accumulate with
treatment time to a desired total impact. The long-term healing process results in
shrinkage of the targeted heart muscle by gradually removing the scattered microle-
sions (regions of dead cells). The progress has succeeded in advancing the small injury
from contrast echo to substantial accumulation of microlesions to form a macrolesion
with up to 21% debulking after 4 weeks healing, while retaining reduced function
in the target volume. Optimization of parameters and methods avoided potentially
harmful premature contraction arrhythmias, reduced the initial swelling and mini-
mized long term scarring for the safe tissue reduction. (Miller et al., 2014a,b, 2015;
Zhu et al., 2015a,b; Lu et al., 2016).
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Figure 6.1: From left to right: A freshly exposed rat heart with capillary hemorrhage
and Evans blue leakage, frozen section histology showing the lethally in-
jured cardiomyocytes in fluorescent red (bar = 2 mm), a heart after 6
weeks of healing with white fibrosis evident (bar = 1 mm), a cross section
of the heart showing fibrosis and wall thinning (arrow, bar = 1 mm), and
histology with the fibrotic regions stained blue covering 15% of the area
(bar = 100 µm).
6.1.2 Dissertation Summary
To this point, this dissertation has demonstrated the assessment of Myocardial
Cavitation-Enabled Therapy (MCET) in acute and chronic studies, and investigates
possible monitoring schemes.
In acute studies, Chapter II describes a computer-aided 3-D objective evalua-
tion scheme developed to characterize macrolesions, including lesion size and lesion
density, for MCET to reduce myocardial tissue. The characterization is based on
brightfield and fluorescence histology images as available in acute preclinical studies.
The radially symmetric model employed to characterize macrolesion density is feasible
for the study using a single focused beam. This methodology reduces visual scoring
ambiguity and provides a volume oriented, quantity-sensitive therapy evaluation. The
comparison of characterized macrolesions to the sham group demonstrates that the
evaluation scheme is robust against noise. Chapter II presents that the quantitative
scoring scheme overcomes the limitation of traditional visual scoring and works for
histological cases with a large lesion count, i.e. has an appropriate dynamic range for
evaluating therapeutic applications. The presented results have shown that MCET-
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induced macrolesions grow radially as the acoustic pressure amplitude increases. A
swept beam as a new method to shorten treatment time seems promising but requires
additional verification to ensure efficacy.
Based on chronic studies, Chapter IV demonstrates that it is promising for MCET
to achieve minimally invasive myocardial tissue reduction by showing quantitative
results of the fibrotic tissue fraction and heart muscle wall reduction induced by
MCET after a long-term (4 week) healing process. It suggests that MCET is an image-
guided method capable of graded and diffuse tissue reduction with potentially minimal
adverse side effects, relative to alcohol ablation or other methods. Improvements are
identified by addition of adjuvant treatment with steroid and antifibrotic medication.
The chronic study in a HCM rat model shows that the MCET method reduced wall
thickness by about 16%, which is a therapeutically useful magnitude. After further
development and refinement of MCET for Hypertrophic Cardiomyopathy (HCM)
should fill the need for new treatment options.
Chapter V investigates the feasibility of microbubble cavitation detection, quan-
tification and localization for treatment monitoring and control. A passive cavitation
imaging algorithm and its variations provide spatial information of cavitation events.
The activities of bubble dynamics and cavitation are mapped in bench-top setups
with a high intensity focused ultrasound (HIFU) transducer and a receive-only pas-
sive imaging array. The higher acoustic response from contrast agents compared
to that from polystyrene spheres in the reconstructed images suggests that cavita-
tion events from agents undergoing inertial cavitation can be detected. Cavitation
sites can be localized with reasonable spatial resolution. The described passive imag-
ing algorithm applies to both systems: Verasonics (an ultrasound research platform)
alone transmitting high intensity focused ultrasound (HIFU) and receiving signals
with cavitation signatures, and Verasonics only for passive receiving with another
HIFU system for therapeutic exposure. The overall therapy-monitoring scheme is
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able to adequately delineate the spatial location of triggered microbubble dynamics
for real-time monitoring of monitoring of microlesion accumulation.
6.2 Discussion
Hypertrophic cardiomyopathy is caused by an increase in myocyte size, but not
myocyte number, and by a greater amount of myocardial fibrosis, which is distributed
throughout the interstium and in discrete foci (Teekakirikul et al., 2012). Specifically
on the cellular level, the hypertrophy results from cellular enlargement in the adult
heart. In addition, structural remodeling of the myocardial cells, including alterations
in the relative proportions of cellular organelles and in the ultrastructure of individual
organelles, occurs during the development of hypertrophy. In contrast, hyperplasia
of myocardial cells happen during embryonic and fetal life which leads to growth of
the vertebrate heart by increase in cell number (Oparil et al., 1984).
The idea behind MCET is to achieve myocardial volume reduction by decreasing
the population of enlarged cells by inducing scattered microlesions freeing their space.
The possibility of natural regeneration of injured cardiomyocyte is minimal. After
cardiomyocyte death, there is no significant replacement of old muscle with new, and
a collagen-rich scar is generated by fibroblasts concomitant with removal of cell debris
(Choi and Poss , 2012). Though numerous research has looked into stem cell based
therapies as a potential alternative therapeutic strategy for myocardial regeneration
and repair, using for example bone marrow derived stem cells (BMCs), adult stem
cells from adipose or cardiac tissue, the current clinical studies haven’t demonstrated
consistent results (Doppler et al., 2013).




A variety of interesting arouse during the course of the therapy. This section will
touch on some including lesion induction, therapy evaluation and monitoring of heart
function.
6.2.1.1 Lesion Induction
As mentioned in Figure 1.2, microbubbles under cavitation may induce a variety
of biological responses.
It is possible that a large semi rigid cell adjacent to a small cavitating bubble
could induce an asymmetric bubble collapse, by which a small jet of liquid would
shoot directly into the cell at sonic speeds, probably rupturing the cell membrane.
Likewise a collapse of a microbubble near a capillary or blood vessel wall will cause
the liquid jet to shoot right into the wall. The induced liquid micro-jets at sonic
velocities may be shooting through cells (and lysing them) (Pitt et al., 2004).
Such may allow large amounts of Red Blood Cell (RBC) and non-destructive
microbubbles to extravasate into the nearby interstitial space where microbubbles
can be further cavitated to damage cells out of vessels (Skyba et al., 1998).
Other than direct damage induced by the liquid jet, blood vessel become injured
by sonic jets, shear stresses, or radicals could generate a nidus for thrombus formation,
which may lead to local ischemia. Depending on ischemia duration, two types of cells
result: viable cells (reversibly injured), and essentially dead cells (irreversibly injured)
(Jennings et al., 1969).
As a schematic illustration of myocardial capillary system, Figure 6.2 shows 5
mum capillaries (Potter and Groom, 1983) and 1 mum diameter microbubbles re-
siding interleaved with 30 mum (Bassien-Capsa et al., 2006) cardiomyoctes. This
distribution of microbubbles in the vessels makes cavitation adjacent to myoctyes
feasible leading to sufficient scattered damage to the myocardium.
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Figure 6.2: (a) Schematic longitudinal section of the myocardial capillary bed and its
anastomoses. (b) Schematic cross-section of the myocardial capillary bed
and cardiac fibers. (Brown, 1965)
The development of MCET has employed Evans blue to identify lethally injured
cells. While Evans blue is a vital dye that is reported to penetrate only damaged
cells (Crutchfield et al., 1999), some false positive events may exist since damaged
or otherwise altered cells may be, though not very likely, capable of repair and be
viable. Ceramide may be a possible indicator of cell apoptosis. Its accumulation has
been found following treatment of cells with a number of apoptotic agents including
ionizing radiation (Haimovitz-Friedman et al., 1994; Dbaibo et al., 1998), UV light
(Rotolo et al., 2005), TNF-alpha (Dbaibo et al., 2001), and chemotherapeutic agents.
However at this stage, the exact viability of cells is not the main interest. Especially,
as described in Chapter IV, the observed level of fibrosis corresponding to therapeutic
conditions confirmed that MCET is capable to induce injuries.
6.2.1.2 Therapy Evaluation
The development of MCET suggests that it is an image-guided method capable of
graded and diffuse tissue reduction with potentially minimal adverse side effects. A
more appropriate comparison for MCET than surgical myectomy (extremely invasive)
may be alcohol septal ablation (ASA).
ASA is a minimally invasive procedure to induce a localized infarct for myocaridal
reduction. A catheter is threaded through the left anterior descending artery into the
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septal perforator with a balloon placed to avoid any antegrade flow into the branch
(Seggewiss et al., 1999). After assessment of the area supplied by the artery, for
example, by contrast-enhanced ultrasound, several milliliters of ethanol are injected
to produce a localized infarct defined by the perfused tissue volume. The proce-
dure typically produces immediate symptomatic relief of the left ventricular outflow
tract (LVOT) obstruction (El Masry and Breall , 2008). This occurs without direct
septal thinning, possibly owing to akinesis of the affected region, which may improve
the dynamic motion and LVOT gradient. Septal thinning develops gradually 3-12
mo after the procedure. Reduction of the interventricular septum from 23.7 to 18.0
mm has been reported 6 mo after ASA (Dabrowski et al., 2012), and the treatment
may result in reduced myocardial mass involving even remote regions (Fifer and Sig-
wart , 2011). The most common serious complication is disruption of the conduction
system, which may include permanent heart block requiring permanent pacemaker
implantation (Sorajja et al., 2008).
The ASA procedure results in a volume of necrosis, including occlusion of the
artery. This volume progresses to myocardial fibrosis and scar (Baggish et al., 2006),
although the healing process is somewhat different from that arising from ischemia, in
that minimal phagocytosis and removal of the necrotic cardiomyocytes occur (Raute-
Kreinsen, 2003). By comparison, the MCET method has a much lower impact on the
conduction system and blood vessels because of the scattered nature induced lesion. A
more defined macrolesion (region of treatment) can be well controlled by placement
of the ultrasonic focus. Electrocardiography (ECG) analysis for MCET revealed
evidence of myocardial cell death with changes consistent with an old infarct by 6
wk, but no evidence of atrioventricular conduction loss or heart block (Lu et al., 2016).
MCET could also potentially treat hypertrophied regions of the heart other than the
septum. This reduced impact may reduce the significant adverse consequences, as
seen for some ASA patients (Folkert et al., 2010).
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6.2.1.3 Therapy Follow-up
Current studies focus on a 6 week followup. Longer studies might also be helpful
to assess safety and efficacy aspects.
Echocardiography is recommended to follow up the treatment for heart function
monitoring, specifically, for left ventricular diastolic function and filling pressures
(Nagueh et al., 2016). This includes Doppler E/e’ ratio, left atrial volume index,
pulmonary vein atrial reversal velocity, and peak velocity of ricuspid regurgitation
jet by CW Doppler (Nagueh et al., 1999). Aside from assessment of left ventricular
filling, 2D and Doppler indices of left ventricular diastolic function provide helpful
prognostic information (Geske et al., 2007).
Ambulatory electrocardiographic monitoring for cardiac conduction system plays
an important role in evaluating heart function, especially detecting arrhythmia re-
sulting from myocardial ablation (Adabag et al., 2005). In addition, left ventricular
diastolic dysfunction causes left ventricular dilatation, which can lead to atrial fibril-
lation (AF) (Tsang et al., 2002). In MCET, ECG analysis has already shown that a
large elevation of the ST segment post treatment, followed by ST-segment suppression
and T-wave inversion the next day, which persisted 6 wk after exposure (Lu et al.,
2016). Further ECG assessment will help assure that MCET is safe in terms of heart
function (arrhythmia).
Additionally, the opportunity for contrast-enhanced cardiac magnetic resonance
(CMR) imaging with late gadolinium enhancement (LGE) to identify areas of myocar-
dial fibrosis is promising for monitoring fibrosis growth after ablation (Rubinshtein
et al., 2009).
6.2.2 Future Directions
To date, the development of MCET has demonstrated treatment response suffi-
cient for potentially advantageous minimally invasive therapy for myocardial reduc-
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tion. Further research is needed to understand the treatment variability, and to assess
possible risks of adverse treatment outcome.
A significant local myocardial reduction was demonstrated but still lack unequiv-
ocal long-term evidence of the therapeutic benefit. The physical dimension of the
employed animal model (rat) is simply too small to investigate any targeted reduc-
tion of the outflow tract obstruction in humans. The size also prevents evaluation
of methods to treat larger volumes by beam scanning or to map the distribution of
microlesions within a given target volume. Investigations in a larger animal model
of HCM (pig) in which conditions similar to those found in the human disease would
be beneficial for the verification of safe and effective treatment outcomes. In the
future, testing of MCET treatment in humans seems premature without evidence of
true therapeutic outcome in a larger animal model. Such would include felines which
naturally develop HCM. The genetic characteristics of mutations in genes that encode
for muscle sarcomeric proteins are similar in cats and humans (Kittleson et al., 2015)
and the feline disease closely models the human disease (Kittleson et al., 1999; Fox
et al., 2014). The feline model appears to be a logical next step in developing MCET
for myocardial reduction therapy, which can be conducted in veterinary hospitals on
cats suffering from life threatening HCM.
With a larger animal model, formulating a set of optimized treatment parameters
to create a desired total volume reduction needs to be addressed considering a more
attenuating acoustic path. Evaluation of beam scanning and to map the distribution
of microlesions within a target volume becomes feasible. In the process of MCET, the
induced scattered mircolesions are injured cells probably resulting from impact from
liquid jets formed during microbubble inertial cavitation. As illustrated in Figure 6.3,
a microbubble experiencing ultrasound can undergo inertial cavitation in a vessel
leading to vascular rupture, which may also be accompanied with damage to adjacent
cells resulting in a microlesion.
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Figure 6.3: Vascular rupture involving a liquid jet. PRPA 4 MPa. Vessel diameter 15
µm. At frame 1.6 µs, a liquid jet appears to be formed inside the bubble
and directed toward the right vessel wall. The jet appears to impact the
vessel wall. At frame 3.4 µs, the re-expanded bubble contracted showing
two connected parts: one outside the vessel and one inside. This leads to
a mushroom-shaped form with its stem stretching through the vessel wall
(frame 4 µs). Sketches of the bubble in the three characteristic frames are
marked with the bubble in solid lines and vessel in dashed lines. In the
last frame, the collapsed bubble (arrow) was observed in the interstitial
space outside the vessel wall frame. (Chen et al., 2010)
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Therefore, future work for MCET monitoring involves development of a coefficient
or transfer function relating cavitation signals to the extent of induced microlesion,
and feasible applications of cavitation imaging techniques for the more compliated
in vivo environment. Furthermore, future implementations will combine biological
responses, for example, premature electrocardiogram complexes from ECG signal
analysis with cavitation activity mapping to predict cell necrosis during the MCET
treatment procedure. Eventually, the monitoring of treatment to provide feedback
and the real-time control for therapy progression will allow for translation to a clinical
setting for cardiac tissue ablation.
Meanwhile, a comprehensive safety analysis is necessary for clinical translation.
Efforts may be undertaken to minimize swelling and scarring of the treated vol-
ume, and to assess potential adverse hemolytic impacts on circulating blood, possible
thrombus initiation by hemolysis or endothelial cell damage.
The overall goal of our MCET investigation will be the introduction of this min-
imally invasive new tool for myocardial reduction therapy for use in human clinical
trials. This innovative technology will advance medical care and improve significantly





Programmable Ultrasound Phased Array Therapy
System
A.1 Background
There has been an emerging interest in high intensity focused ultrasound (HIFU)
for therapeutic applications. By means of its thermal or mechanical effects, HIFU is
able to serve as a direct tool for tissue ablation, or an indirect moderating medium
to manipulate microbubbles or perform heating (hyperthermia) for the purpose of
targeted drug delivery. The development and testing of HIFU based phased arrays
is favorable as their elements allow for individual phasing to steer and focus the
beam. While FDA has already approved tissue ablation by HIFU for the treatment of
uterine fibroids (2004) and pain from bone metastases (2012), development continues
on other possible applications that are less forgiving of incomplete treatment, such as
thermal necrosis of malignant masses. Ongoing efforts investigate how to maintain
focusing through or around aberrating structures, how to minimize damage to tissue
surrounding the target area, safely increase focal power, and how to steer in aberrating
three-dimensional space.
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Ideally, each element, of such an array must have its own fully programmable
electrical driving channel, which allows the control of delay, phase, and amplitude of
the output from each element. To enable full control, each channel needs a waveform
generator, an amplification device, and an impedance matching circuit between driver
and acoustic element.
Similar projects utilizing this approach to drive therapeutic arrays include a 512-
channel therapy system which was built at the University of Michigan using low
cost Field-Programmable Gate Arrays (FPGA) microcontroller and highly efficient
MOSFET switching amplifiers (Hall et al., 2006). However, this system lacks the
ability to drive both, continuous wave (CW) and transient short duty-cycle high
power pulses.
Here presents a hybrid system, which is able to perform CW and transient short
duty-cycle high power excitation. In the following we will describe the design, pro-
gramming, fabrication, and evaluation of this radio frequency (RF) driver system as
used in our laboratory for a 1.5 MHz center frequency, 298-element array (Imasonic
SA, Besancon, France) (Kripfgans et al., 2012), HIFU-controlled amplifier boards
and matching circuitry. Advantages of our design include: 1. Inexpensive compo-
nents (<$15/channel); 2. Ability to program/drive individual output channels inde-
pendently; 3. Sufficient time and amplitude resolution for various acoustic pattern
design; 4. Capability of hybrid switching between low power CW and short duty
cycle, high instantaneous power .
A.2 Methods
Our HIFU driving system was designed and assembled at the University of Michi-
gan. The FPGA system controls 20 amplifier boards (Umemura and Cain, 1992),
which each controls 16 RF channels, thus in total independently drive up to 320
channels (298 used).
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The overall control flow from user inputs to RF outputs is described as in Fig-
ure A.1. The system uses 11 FPGA boards (1 synchronizing master board and 10
client boards). The master provides clock (100 MHz) and trigger signals to each
client. Each FPGA board has 8 MB SDRAM storage and is able to control a max-
imum of 32 RF output channels (16 positive and 16 negative controls of 16 P- and
N-channel MOSFET pairs). For each channel, frequency, burst length, amplitude,
and delay can be programmed.
Figure A.1: HIFU system control flow. Frontend software control allows the user
to select a series of desired ultrasound focal locations and individual
pressure amplitudes. These are processed based on acoustic and electric
calibration of the HIFU array and then communicated to the hardware
backend. All 320 RF channels are driven in parallel and in real-time
through asynchronous FPGA microcontrollers. The frontend is used to
setup each channel and to start the general HIFU exposure. Sequential
focal locations are internally triggered by the backend and controlled
using local on-board SDRAM.
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A MATLAB based Graphical User Interface (GUI) with entries of [position #,
repetition #] as a task list was developed to program the output sequences and
patterns for all channels. Figure A.2 illustrates the idea of high speed execution of
complex HIFU exposure patterns by storing HIFU settings for each position in the
local FPGA SDRAM. Indexed positions are called in sequence from a task list, that
is also stored in SDRAM. This enables the HIFU system to run autonomously and
asynchronous from the frontend at an up to 20 kHz position switching rate, which is
limited by the SDRAM page read time of 50 s total. Positions define spatial location
of the HIFU beam, the wave frequency, burst length, pressure amplitude, and delay
for all 320 channels. Pressure is based on calibration data. The task list is set through
the frontend GUI and communicated through USB to the backend. Our HIFU system
allows up to 16,000 individual ‘positions’ and 23,000 tasks, where each task can repeat
a given ‘position’ up to 255 times. Complex exposure patterns can be generated by
manipulating tasks and ‘positions’, e.g. triggers generated by the master board, can
be of zero amplitude and x-number of cycles, thus defining a user specified pause.
The evaluations for this system were performed to examine the following aspects:
(1) Output acoustic pressure measured by a hydrophone in water tank; (2) Electrical
power output per channel including peak-output performance and time-average power
performance.
A.3 Results
Our phased array HIFU therapy system is able to produce >25 MPa peak negative
pressure amplitudes for electronically steered beam positions. The system consists of
320 fully programmable individual broadband channels capable of generating bursts
of digital waveforms with 10 ns resolution in a frequency range of 1.5 kHz to 50 MHz.
The generated RF waveforms show a root-mean-square jitter of 2.5 ns with a
standard deviation of 1.9 ns, well under the inherent 10 ns system clock resolution.
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Figure A.2: Illustration of position indexing executed by a task list. User composes
a list of tasks (T1, T2, , TN), each repeatable between 1 and 255 times
(repetition #). The task list indices refer to ‘positions’ stored in client
board SDRAM. Each of the 10 client boards stores 32 sets of delay, burst
length, and number of on/off cycles, for its local 32 channels. (Note:
On and Off determine the duty-cycle for each period, thereby controlling
the amount of charge able to accumulate on each probe element, and
therefore controlling the output pressure, i.e. 10%/20% duty cycle will
yield a 20%/100% acoustic pressure, respectively). For every trigger the
task pointer advances from n to n+1, calling the associated position #
and programming the RF pulse generator. Each position can be repeated
up to 255 times.
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The usual electrical to acoustical energy transfer efficiency to our specific physical
HIFU array is 70%. Electrical drive amplitudes were limited to 450 Vpp to protect
the HIFU array elements composite materials.
Peak-output power performance: short-time performance (< 7µs) allowed for up
to 18 Watts of electrical power per channel and produced 30 kW/cm2 acoustically.
Time-average power performance: long-time (CW) performance (<5 s) achieved up
to 1 Watt of electrical power per channel and produced 1.7 kW/cm2 acoustically.
This HIFU system has been validated in Myocardial Cavitation-Enabled Ther-
apy (MCET), where ECG triggering was used to perform a therapy pulse every 8
heartbeats as illustrated in Figure A.3, and treatment paused for heartbeats 2 to
8. Here, therapy is defined as a complex pattern of 4 successive transmits, 250 µs
apart. Each transmit consists of a 10-cycle, 1.5 MHz center frequency tone burst
with 4 MPa peak rarefactional pressure amplitude (PRPA). The master board sends
4 trigger signals, 250 µs apart, for every external trigger (i.e. from ECG system).
The task list contains two items: (1) an active item, fire at a given coordinate, repeat
4 times (=1×4), and (2) a passive item, pause the system (zero amplitude) by not
firing, repeat 28 times (=7×4).
A.4 Interpretation
Here presents a low-cost programmable hybrid HIFU system, providing a design
potentially attractive to ultrasonic therapy projects with complex demands. The
system is capable to operate in high power (40 MPa peak-to-peak) low duty cycle
(1%) pulses or low power (5 MPa peak-to-peak) high duty cycle (98%), beneficial
to both mechanical (e.g. MCET and histotripsy) and thermal (e.g. hyperthermia)
based therapy. The structured FPGA control framework includes a synchronizing
master board and independent client boards both controlled using one Verilog file.
The system can be easily configured to drive a flexible number of channels by simply
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Figure A.3: Illustration of position indexing executed by the task list used for MCET
therapy (10-cycle 1.5 MHz center frequency bursts, 4 MPa peak rarefac-
tional pressure, 4 repetitions at 4 kHz every 8 heartbeats.
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adding client FPGA boards/amplifiers. The driving circuits employ standard, non-
expensive, off-the-shelf components. Commercial signal/power generators that would
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